Orris

Brain tumors

Reading File
Brain tumors is a broad topic. Let me clarify what would be most helpful for you.
Asking for Preferences

What aspect of brain tumors are you most interested in? · What is your background/purpose?

I am Radiology resident I am having seminar on topic of Intra axial brain tumors ,so provide in depth knowledge about intra axial tumours,what to add in intraaxial tumours and explain all in depth,add extra other things as you think if needed

Searching sources...
Finding Sources
Finding Sources
Searching PubMed

intra-axial brain tumors MRI imaging classification

Finding Sources
Finding Sources
Searching Images

glioblastoma MRI brain tumor imaging

This diagnostic comparison chart displays multi-modal brain imaging for a high-grade glioblastoma (upper row) and a low-grade glioma (lower row) across four modalities: contrast-enhanced T1-weighted MRI (T1ce), amide proton transfer-weighted (APTw) MRI, FET PET, and normalized cerebral blood volume (nCBV) maps. Column (a) shows T1ce MRI with segmentation overlays: red indicates contrast-enhancing tumor (CET) and green highlights FLAIR hyperintense tumor (FHT). In the glioblastoma, CET and FHT are more extensive and irregular compared to the circumscribed regions in the low-grade glioma. Column (b) presents APTw imaging, where the glioblastoma exhibits higher yellow-green signal intensity, signifying increased endogenous protein/cellularity. Column (c) FET PET images demonstrate significantly higher amino acid uptake (red hot spots) in the glioblastoma, indicating higher metabolic activity. Column (d) nCBV maps show increased perfusion (red/yellow areas) in the glioblastoma, reflecting higher vascularity. This comparison highlights how multi-parametric advanced imaging differentiates tumor grades based on cellularity, metabolism, and hemodynamics.

This diagnostic comparison chart displays multi-modal brain imaging for a high-grade glioblastoma (upper row) and a low-grade glioma (lower row) across four modalities: contrast-enhanced T1-weighted MRI (T1ce), amide proton transfer-weighted (APTw) MRI, FET PET, and normalized cerebral blood volume (nCBV) maps. Column (a) shows T1ce MRI with segmentation overlays: red indicates contrast-enhancing tumor (CET) and green highlights FLAIR hyperintense tumor (FHT). In the glioblastoma, CET and FHT are more extensive and irregular compared to the circumscribed regions in the low-grade glioma. Column (b) presents APTw imaging, where the glioblastoma exhibits higher yellow-green signal intensity, signifying increased endogenous protein/cellularity. Column (c) FET PET images demonstrate significantly higher amino acid uptake (red hot spots) in the glioblastoma, indicating higher metabolic activity. Column (d) nCBV maps show increased perfusion (red/yellow areas) in the glioblastoma, reflecting higher vascularity. This comparison highlights how multi-parametric advanced imaging differentiates tumor grades based on cellularity, metabolism, and hemodynamics.

This Comparison Chart displays serial axial T1-weighted post-contrast MRI slices (Slices 15–18) of a patient with glioblastoma, comparing two clinical time points: 'Within 90 days after completing CRT' and 'At the progression state'. The layout is organized into three columns for each state: 'Brain MRI' (standard imaging), 'Brain tissue' (segmented parenchyma), and 'Tumor area' (isolated segmentation of the lesion).

This Comparison Chart displays serial axial T1-weighted post-contrast MRI slices (Slices 15–18) of a patient with glioblastoma, comparing two clinical time points: 'Within 90 days after completing CRT' and 'At the progression state'. The layout is organized into three columns for each state: 'Brain MRI' (standard imaging), 'Brain tissue' (segmented parenchyma), and 'Tumor area' (isolated segmentation of the lesion).

This diagnostic image displays axial 18F-FDOPA PET/MRI scans of the brain, comparing two patients with IDH-wildtype glioblastoma to demonstrate the effect of carbidopa premedication on image contrast. The visualization uses two imaging metrics: Standardized Uptake Value (SUV) and Tumor-to-Healthy-Brain Ratio (TBR). Row A (no carbidopa) shows a localized high-intensity SUV signal in the left hemisphere glioblastoma with low background uptake in healthy brain tissue. Row B (with carbidopa) illustrates significantly increased background SUV throughout the striatum and cortex, which reduces the visual contrast between the tumor and healthy tissue on the SUV parametric map. The corresponding TBR parametric images (right column) demonstrate how normalizing the signal to healthy brain tissue improves tumor definition and contrast, particularly in the premedicated patient (B) where the tumor otherwise blends with the elevated background. A color scale indicates SUV values from 0 to 4. This comparison is clinically relevant for neuro-oncology imaging protocols, highlighting how carbidopa increases tracer availability and the necessity of TBR maps for accurate tumor delineation.

This diagnostic image displays axial 18F-FDOPA PET/MRI scans of the brain, comparing two patients with IDH-wildtype glioblastoma to demonstrate the effect of carbidopa premedication on image contrast. The visualization uses two imaging metrics: Standardized Uptake Value (SUV) and Tumor-to-Healthy-Brain Ratio (TBR). Row A (no carbidopa) shows a localized high-intensity SUV signal in the left hemisphere glioblastoma with low background uptake in healthy brain tissue. Row B (with carbidopa) illustrates significantly increased background SUV throughout the striatum and cortex, which reduces the visual contrast between the tumor and healthy tissue on the SUV parametric map. The corresponding TBR parametric images (right column) demonstrate how normalizing the signal to healthy brain tissue improves tumor definition and contrast, particularly in the premedicated patient (B) where the tumor otherwise blends with the elevated background. A color scale indicates SUV values from 0 to 4. This comparison is clinically relevant for neuro-oncology imaging protocols, highlighting how carbidopa increases tracer availability and the necessity of TBR maps for accurate tumor delineation.

A multi-panel diagnostic imaging series demonstrating tumor microenvironment (TME) mapping across four brain tumor types: (A) Glioblastoma WHO grade 4, (B) Brain metastasis from breast cancer, (C) Primary central nervous system lymphoma (PCNSL), and (D) Meningioma. For each entity, axial MRI slices are presented across five modalities: Conventional CE T1w, FLAIR, tissue oxygen tension (PO2) maps, neovascularization activity (MTI) maps, and color-coded TME maps. Corresponding radar charts quantify metabolic compartments: Glycolysis (blue), Oxidative Phosphorylation (OxPhos, green), Necrosis (black), and Hypoxia (red/yellow). Glioblastoma (A) shows high heterogeneity with central necrosis and a significant hypoxic rim. The metastasis (B) shows a larger necrotic center compared to hypoxia. PCNSL (C) and Meningioma (D) exhibit metabolic dominance in aerobic glycolysis (65-71%) with higher oxygen tension and functional neovascularization, showing minimal necrosis. This visual data illustrates how advanced MRI mapping can differentiate tumor physiology based on metabolic signatures and vascular integrity.

A multi-panel diagnostic imaging series demonstrating tumor microenvironment (TME) mapping across four brain tumor types: (A) Glioblastoma WHO grade 4, (B) Brain metastasis from breast cancer, (C) Primary central nervous system lymphoma (PCNSL), and (D) Meningioma. For each entity, axial MRI slices are presented across five modalities: Conventional CE T1w, FLAIR, tissue oxygen tension (PO2) maps, neovascularization activity (MTI) maps, and color-coded TME maps. Corresponding radar charts quantify metabolic compartments: Glycolysis (blue), Oxidative Phosphorylation (OxPhos, green), Necrosis (black), and Hypoxia (red/yellow). Glioblastoma (A) shows high heterogeneity with central necrosis and a significant hypoxic rim. The metastasis (B) shows a larger necrotic center compared to hypoxia. PCNSL (C) and Meningioma (D) exhibit metabolic dominance in aerobic glycolysis (65-71%) with higher oxygen tension and functional neovascularization, showing minimal necrosis. This visual data illustrates how advanced MRI mapping can differentiate tumor physiology based on metabolic signatures and vascular integrity.

This diagnostic imaging panel provides a comparative analysis of positron emission tomography (PET) and magnetic resonance imaging (MRI) in a rat brain glioblastoma model. The top row displays axial PET scans using two different radiopharmaceuticals: O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), which targets amino acid transport, and [18F]fluoroazomycin arabinoside ([18F]FAZA), which targets tissue hypoxia. Both tracers show increased focal uptake (indicated by red/yellow pseudocoloring) within the tumor region. [18F]FET exhibits higher overall brain background and more uniform tumor delineation, whereas [18F]FAZA shows a more speckled, heterogeneous distribution reflecting hypoxic sub-volumes. The bottom row consists of corresponding contrast-enhanced T1-weighted MRI scans. These scans show a focal region of hyperintensity (gadolinium enhancement) indicative of blood-brain barrier disruption. A white boundary line is used across all modalities to delineate the anatomical extent of the rat brain. The image illustrates the clinical utility of multi-modal imaging to identify different physiological characteristics of glioblastoma, such as metabolic activity versus hypoxia, which is critical for targeted radiotherapy planning.

This diagnostic imaging panel provides a comparative analysis of positron emission tomography (PET) and magnetic resonance imaging (MRI) in a rat brain glioblastoma model. The top row displays axial PET scans using two different radiopharmaceuticals: O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), which targets amino acid transport, and [18F]fluoroazomycin arabinoside ([18F]FAZA), which targets tissue hypoxia. Both tracers show increased focal uptake (indicated by red/yellow pseudocoloring) within the tumor region. [18F]FET exhibits higher overall brain background and more uniform tumor delineation, whereas [18F]FAZA shows a more speckled, heterogeneous distribution reflecting hypoxic sub-volumes. The bottom row consists of corresponding contrast-enhanced T1-weighted MRI scans. These scans show a focal region of hyperintensity (gadolinium enhancement) indicative of blood-brain barrier disruption. A white boundary line is used across all modalities to delineate the anatomical extent of the rat brain. The image illustrates the clinical utility of multi-modal imaging to identify different physiological characteristics of glioblastoma, such as metabolic activity versus hypoxia, which is critical for targeted radiotherapy planning.

This composite of six axial brain MRI scans demonstrates a glioblastoma (GBM) and its progression over a 7-month interval. (A) T2-FLAIR image shows a hyperintense mass involving the septum pellucidum and corpus callosum with associated perilesional edema. (B) Contrast-enhanced T1-weighted (CE T1W) image displays the primary tumor's heterogeneous enhancement, signifying blood-brain barrier disruption. (C) A Ve map (extracellular extravascular volume fraction) highlights increased vascular permeability, with arrows pointing to focal areas of elevated Ve. (D) A predictive MRI model overlay identifies a high-risk region (red) for local recurrence within the non-enhancing T2 hyperintense zone. (E, F) Longitudinal follow-up CE T1W scans at 7 months confirm disease progression, evidenced by a new, measurable enhancing lesion at the genu of the corpus callosum. This sequence illustrates the clinical utility of combining conventional imaging with physiological MRI parameters (like Ve maps) and predictive modeling to anticipate sites of glioblastoma recurrence beyond the initial contrast-enhancing tumor margins.

This composite of six axial brain MRI scans demonstrates a glioblastoma (GBM) and its progression over a 7-month interval. (A) T2-FLAIR image shows a hyperintense mass involving the septum pellucidum and corpus callosum with associated perilesional edema. (B) Contrast-enhanced T1-weighted (CE T1W) image displays the primary tumor's heterogeneous enhancement, signifying blood-brain barrier disruption. (C) A Ve map (extracellular extravascular volume fraction) highlights increased vascular permeability, with arrows pointing to focal areas of elevated Ve. (D) A predictive MRI model overlay identifies a high-risk region (red) for local recurrence within the non-enhancing T2 hyperintense zone. (E, F) Longitudinal follow-up CE T1W scans at 7 months confirm disease progression, evidenced by a new, measurable enhancing lesion at the genu of the corpus callosum. This sequence illustrates the clinical utility of combining conventional imaging with physiological MRI parameters (like Ve maps) and predictive modeling to anticipate sites of glioblastoma recurrence beyond the initial contrast-enhancing tumor margins.

Reading File
Finding Sources
Searching Images

brain tumor MRI classification types low grade high grade glioma lymphoma metastasis

Reading File
Finding Sources
Searching Images

medulloblastoma posterior fossa MRI cerebellum child

Reading File
Finding Sources
Reading File
Reading File
Reading File
Searching Images

primary CNS lymphoma PCNSL MRI basal ganglia periventricular

This composite diagnostic image displays MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans for six different patients, illustrating various manifestations of hematologic Central Nervous System (CNS) disease. The top row primarily features axial and sagittal MRI views, while the bottom row includes complementary coronal MRI and PET fusion images. Patient 1 shows secondary CNS lymphoma (SCNSL) with an intramedullary lesion in the cervical spinal cord on sagittal MRI, matched with focal hypermetabolism on a PET/CT neck axial slice. Patients 2 and 3 demonstrate parenchymal SCNSL; Patient 2 exhibits a contrast-enhancing mass in the right basal ganglia/thalamic region, and Patient 3 shows a left frontal lobe lesion with surrounding vasogenic edema. Patients 4 and 5 illustrate Primary CNS Lymphoma (PCNSL), showing periventricular and multifocal enhancing masses respectively. Patient 6 depicts leptomeningeal diffuse infiltration associated with leukemia, showing less focal mass effect but subtle enhancement patterns. The images serve as an educational comparison of intracranial and intraspinal lymphoproliferative involvement, highlighting differing morphologies such as focal parenchymal masses, leptomeningeal spread, and spinal cord expansion.

This composite diagnostic image displays MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans for six different patients, illustrating various manifestations of hematologic Central Nervous System (CNS) disease. The top row primarily features axial and sagittal MRI views, while the bottom row includes complementary coronal MRI and PET fusion images. Patient 1 shows secondary CNS lymphoma (SCNSL) with an intramedullary lesion in the cervical spinal cord on sagittal MRI, matched with focal hypermetabolism on a PET/CT neck axial slice. Patients 2 and 3 demonstrate parenchymal SCNSL; Patient 2 exhibits a contrast-enhancing mass in the right basal ganglia/thalamic region, and Patient 3 shows a left frontal lobe lesion with surrounding vasogenic edema. Patients 4 and 5 illustrate Primary CNS Lymphoma (PCNSL), showing periventricular and multifocal enhancing masses respectively. Patient 6 depicts leptomeningeal diffuse infiltration associated with leukemia, showing less focal mass effect but subtle enhancement patterns. The images serve as an educational comparison of intracranial and intraspinal lymphoproliferative involvement, highlighting differing morphologies such as focal parenchymal masses, leptomeningeal spread, and spinal cord expansion.

Searching Images

oligodendroglioma calcification MRI CT brain

Imaging modality and technique: Non-contrast CT of the brain is the primary image, with axial sections demonstrating a well circumscribed, extra-axial mass located at the anterior cranial fossa near the frontal convexity. The lesion is markedly hyperdense due to dense calcification, with coarse calcifications producing bright foci that obscure the underlying cortex. The mass abuts the dura and appears to cause mild mass effect on the adjacent frontal lobes, but there is no midline shift or intraventricular hemorrhage. The appearance is classic for a calcified meningioma; the tumor originates from the dura and demonstrates dural-based expansion, with a possible dural tail on the MRI counterpart. The MRI image (not shown here) would typically show a lesion with variable T1/T2 signal and strong, homogeneous enhancement after gadolinium, consistent with meningioma and predominance of calcified components. Clinically, incidental discovery of a calcified meningioma aligns with a slow-growing, benign meninges-derived neoplasm. Differential considerations include psammomatous meningioma, calcified oligodendroglioma (intra-axial), calcified metastasis, and dural-based schwannoma; however, location and extra-axial behavior with dense calcifications favor meningioma. Diagnostic significance is that surgical resection often yields cure; prognosis depends on size, location, edema, and invasion; radiologic monitoring is advised.

Imaging modality and technique: Non-contrast CT of the brain is the primary image, with axial sections demonstrating a well circumscribed, extra-axial mass located at the anterior cranial fossa near the frontal convexity. The lesion is markedly hyperdense due to dense calcification, with coarse calcifications producing bright foci that obscure the underlying cortex. The mass abuts the dura and appears to cause mild mass effect on the adjacent frontal lobes, but there is no midline shift or intraventricular hemorrhage. The appearance is classic for a calcified meningioma; the tumor originates from the dura and demonstrates dural-based expansion, with a possible dural tail on the MRI counterpart. The MRI image (not shown here) would typically show a lesion with variable T1/T2 signal and strong, homogeneous enhancement after gadolinium, consistent with meningioma and predominance of calcified components. Clinically, incidental discovery of a calcified meningioma aligns with a slow-growing, benign meninges-derived neoplasm. Differential considerations include psammomatous meningioma, calcified oligodendroglioma (intra-axial), calcified metastasis, and dural-based schwannoma; however, location and extra-axial behavior with dense calcifications favor meningioma. Diagnostic significance is that surgical resection often yields cure; prognosis depends on size, location, edema, and invasion; radiologic monitoring is advised.

Reading File
Searching Images

brain tumor MRI perfusion DWI spectroscopy advanced imaging

This composite of six diagnostic images illustrates the multidimensional MRI and spectroscopic profile of a localized lesion in the left parietal lobe, characteristic of epithelioid glioblastoma (eGBM). (a) Axial T2-weighted imaging (T2WI) shows a hyperintense lesion involving the cortical and subcortical white matter with clear boundaries and minimal peritumoral edema. (b) Diffusion-weighted imaging (DWI) reveals high signal intensity, which corresponds to low signal intensity on the (d) Apparent Diffusion Coefficient (ADC) map, indicating restricted diffusion within the tumor parenchyma. (c) Coronal contrast-enhanced T1-weighted imaging demonstrates obvious, uniform enhancement of the lesion and a visible 'meningeal tail sign' (white arrow), suggesting dural involvement. (e) MR perfusion imaging (PWI) shows significantly increased cerebral blood flow (rCBF) in the lesion area (red/warm colors), reflecting high vascularity. (f) MR spectroscopy (MRS) graph displays an elevated Choline (Cho) peak and a markedly reduced N-acetylaspartate (NAA) peak, resulting in a high Cho/NAA ratio characteristic of high-grade malignancy. This multimodal presentation is a key educational example of how advanced imaging sequences differentiate aggressive brain tumors from other cerebral pathologies.

This composite of six diagnostic images illustrates the multidimensional MRI and spectroscopic profile of a localized lesion in the left parietal lobe, characteristic of epithelioid glioblastoma (eGBM). (a) Axial T2-weighted imaging (T2WI) shows a hyperintense lesion involving the cortical and subcortical white matter with clear boundaries and minimal peritumoral edema. (b) Diffusion-weighted imaging (DWI) reveals high signal intensity, which corresponds to low signal intensity on the (d) Apparent Diffusion Coefficient (ADC) map, indicating restricted diffusion within the tumor parenchyma. (c) Coronal contrast-enhanced T1-weighted imaging demonstrates obvious, uniform enhancement of the lesion and a visible 'meningeal tail sign' (white arrow), suggesting dural involvement. (e) MR perfusion imaging (PWI) shows significantly increased cerebral blood flow (rCBF) in the lesion area (red/warm colors), reflecting high vascularity. (f) MR spectroscopy (MRS) graph displays an elevated Choline (Cho) peak and a markedly reduced N-acetylaspartate (NAA) peak, resulting in a high Cho/NAA ratio characteristic of high-grade malignancy. This multimodal presentation is a key educational example of how advanced imaging sequences differentiate aggressive brain tumors from other cerebral pathologies.

Loading Image
Loading Image
Searching the Web

WHO 2021 CNS tumor classification 5th edition intra-axial brain tumors radiology updates

Loading Image
Loading Image
Here is a comprehensive, seminar-level guide to Intra-Axial Brain Tumors for your radiology presentation:

INTRA-AXIAL BRAIN TUMORS

A Comprehensive Radiology Seminar Guide

1. DEFINITION AND FUNDAMENTAL CONCEPT

Intra-axial tumors arise from within the brain parenchyma itself - from the neurons, glial cells, ependymal cells, or any tissue intrinsic to the brain substance. This distinguishes them fundamentally from extra-axial tumors (meningiomas, schwannomas, epidermoids), which arise outside the brain but compress or displace it.

Key Radiological Signs That Confirm Intra-Axial Origin:

  • No CSF cleft between lesion and brain
  • No buckling/displacement of gray-white matter interface
  • No broad dural base
  • Epicenter within brain parenchyma
  • Surrounding infiltrative edema rather than compressed cortex

2. WHO CNS CLASSIFICATION - UNDERSTANDING THE EVOLUTION

This is the single most important conceptual shift for any modern neuroradiology seminar.

WHO 2016 (4th Edition - Major Paradigm Shift)

Introduced molecular markers into diagnosis for the first time - the "layered diagnosis":
  • IDH mutation status
  • 1p/19q codeletion
  • MGMT promoter methylation
Tumor TypeICD-O Code
Glioblastoma, IDH-wildtype9440/3
Glioblastoma, IDH-mutant9445/*
Diffuse astrocytoma, IDH-mutant9400/3
Oligodendroglioma, IDH-mutant AND 1p/19q-codeleted9450/3
Diffuse midline glioma, H3 K27M-mutant9385/*

WHO 2021 (5th Edition - Current Standard)

The 2021 WHO CNS5 classification introduced several major updates:
  • Arabic numerals replace Roman numerals for grading (Grade 4, not Grade IV)
  • Within-type grading - grade is assigned within a tumor type, not across all CNS tumors
  • DNA methylation profiling added as a diagnostic tool
  • 22 newly recognized tumor entities added
  • Greater separation between pediatric-type and adult-type diffuse gliomas
  • Astrocytoma, IDH-mutant is now graded 2, 3, or 4 (previously only grade 2-3 for astrocytoma; grade 4 was called GBM)

3. CLASSIFICATION OF INTRA-AXIAL TUMORS

A. Diffuse Glial Tumors (Most Common - 50-70% are high grade)

  1. Glioblastoma, IDH-wildtype (Grade 4)
  2. Astrocytoma, IDH-mutant (Grade 2, 3, 4)
  3. Oligodendroglioma, IDH-mutant + 1p/19q codeleted (Grade 2, 3)
  4. Diffuse midline glioma, H3 K27M-mutant (Grade 4)
  5. Diffuse hemispheric glioma, H3 G34-mutant (Grade 4) - NEW in 2021

B. Circumscribed Gliomas

  1. Pilocytic astrocytoma (Grade 1)
  2. Pleomorphic xanthoastrocytoma (PXA) (Grade 2, 3)
  3. Subependymal giant cell astrocytoma (SEGA) (Grade 1)

C. Glioneuronal & Neuronal Tumors

  1. Ganglioglioma (Grade 1-3)
  2. Dysembryoplastic neuroepithelial tumor (DNET) (Grade 1)
  3. Central neurocytoma
  4. Cerebellar liponeurocytoma

D. Ependymal Tumors

  1. Ependymoma (Grade 2-3)
  2. Myxopapillary ependymoma (Grade 2)
  3. Subependymoma (Grade 1)
  4. Ependymoma, RELA-fusion positive (now called supratentorial ependymoma, ZFTA fusion-positive in WHO 2021)

E. Embryonal Tumors (predominantly pediatric)

  1. Medulloblastoma (all grades)
  2. CNS embryonal tumor (Grade 4)

F. Other Intra-Axial Entities (non-primary)

  1. Brain metastases
  2. Primary CNS Lymphoma (PCNSL)
  3. Tumefactive MS (mimicker)
  4. Brain abscess (mimicker)

4. GLIOBLASTOMA (GBM) - THE MOST IMPORTANT TUMOR

Epidemiology

  • Most common primary malignant brain tumor in adults
  • Peak incidence: 55-75 years
  • Median survival: 12-14 months even with maximal treatment (surgery + RT + TMZ)
  • M:F ratio approximately 1.6:1

Molecular Biology (Critical for Radiology Reports)

MarkerSignificance
IDH statusWild-type = primary GBM (>90%), worst prognosis
MGMT methylationPredicts response to temozolomide; better prognosis
EGFR amplificationCommon in IDH-wt GBM
TERT mutationCommon in IDH-wt GBM

Imaging Features

CT:
  • Heterogeneous hypodense mass with irregular peripheral hyperdense rim (blood)
  • Surrounding vasogenic edema
  • Mass effect, midline shift
  • Avid, irregular ring enhancement
MRI - Conventional:
  • T1: Heterogeneous, central hypointensity (necrosis)
  • T2/FLAIR: Extensive surrounding hyperintensity - the T2/FLAIR halo ALWAYS contains infiltrating tumor cells (not just edema)
  • T1+Gd: Thick, nodular, irregular ring enhancement - hallmark
  • DWI/ADC: Restricted diffusion in solid components (high cellularity); low ADC in enhancing margins
GBM MRI: T2 heterogeneous mass with surrounding edema, post-Gd ring enhancement, ADC restricted diffusion - Grainger & Allison's Radiology
Classic GBM: (A) T2 - heterogeneous right hemisphere mass with surrounding edema; (B) Post-Gd T1 - no enhancement in this IDH-wt case (note: non-enhancing GBMs exist!); (C) ADC - restricted diffusion within the solid component
MRI - Advanced/Functional:
ModalityGBM FindingSignificance
DSC Perfusion (rCBV)Markedly elevated (>1.75 cutoff)Neovascularity / angiogenesis
MRSElevated Cho, reduced NAA, Cho/NAA >2, lipid/lactate peaksHigh cellularity + necrosis
DWIRestricted diffusion in cellular areasHigh tumor grade
fMRIMaps eloquent cortexPre-surgical planning
DTIWhite matter tract displacement vs. infiltrationSurgery planning

Butterfly GBM - High Yield Pattern

Bilateral hemispheric involvement crossing the corpus callosum. The CC is involved in 5% of GBMs at presentation. Differential: PCNSL, tumefactive MS, lymphoma.

GBM Treatment Response Monitoring

A critical concept for radiologists:
  • Pseudoprogression: Apparent increase in enhancement within 3 months of RT + TMZ - represents treatment effect, not true progression. More common with MGMT-methylated tumors.
  • Pseudoresponse: Apparent decrease in enhancement with anti-VEGF therapy (bevacizumab) - the tumor shrinks its enhancement but continues growing as non-enhancing T2/FLAIR disease.
  • RANO criteria: Standardized bidirectional measurements for treatment response; requires combining enhancing AND non-enhancing T2/FLAIR changes.

5. IDH-MUTANT GLIOMAS (Lower Grade)

The IDH Mutation - Why It Matters

IDH1 (R132H, found in ~90% of IDH-mutant gliomas) and IDH2 mutations produce the oncometabolite 2-hydroxyglutarate (2-HG). Despite being "mutant," IDH-mutant gliomas have significantly better prognosis (survival often 5-10+ years vs. 12-14 months for GBM).
IDH-mutant gliomas are divided by 1p/19q codeletion:
  • 1p/19q codeleted → Oligodendroglioma (best prognosis, ~8 years mean survival)
  • No 1p/19q codeletion → Astrocytoma, IDH-mutant (intermediate prognosis)

Imaging Features of IDH-Mutant Low-Grade Gliomas

General Features:
  • Young adults (mean age 30-40 years)
  • Often cortically based, frontal lobe predominance
  • Seizures as presenting symptom
  • Well-defined, non-enhancing (usually)
  • T2/FLAIR hyperintense without much surrounding edema (unlike GBM)
Oligodendroglioma (IDH-mutant, 1p/19q codeleted):
  • Cortically based, frequently frontal lobe (70%)
  • Calcification in ~70-90% (coarse, irregular) - best seen on CT
  • T2 heterogeneous with cysts
  • Enhancement variable
  • Can have paradoxically elevated rCBV despite low grade (due to branching "chicken-wire" vasculature)
Astrocytoma, IDH-mutant:
  • Diffuse, infiltrating
  • T2/FLAIR homogeneous hyperintensity
  • Usually non-enhancing at Grade 2; enhancement signals Grade 3-4
  • Lower rCBV than oligodendroglioma
IDH-wt astrocytoma MRI: T2, post-Gd T1, DWI, ADC - Grainger & Allison's
IDH-wildtype astrocytoma (WHO Grade 3): (A) T2 hyperintense; (B) Post-Gd - no enhancement (note non-enhancing GBMs are more common than thought); (C) DWI - no significant restriction; (D) ADC - elevated signal

6. DIFFUSE MIDLINE GLIOMA (H3 K27M-Mutant) - HIGH YIELD

  • WHO Grade 4 - all cases, regardless of histology
  • Predominantly pediatric/young adults
  • Location: Brainstem (especially pons = DIPG), thalamus, spinal cord
  • The H3 K27M mutation (histone mutation) is the defining molecular feature
  • Imaging: Diffuse, infiltrating pontine/thalamic mass, variable enhancement, often no necrosis
  • Prognosis: Median survival ~10-12 months despite treatment
Radiological tip: A child with a diffuse, infiltrative pontine mass that wraps around the basilar artery and does NOT enhance dramatically = DIPG until proven otherwise.

7. CIRCUMSCRIBED GLIOMAS

Pilocytic Astrocytoma (Grade 1)

  • Most common brain tumor in children overall
  • Location: Cerebellum (most common), optic pathway, hypothalamus, brainstem
  • Classic MRI: Cyst with enhancing mural nodule - "cyst + nodule" pattern
  • The cyst wall does NOT enhance; the mural nodule enhances avidly
  • Leptomeningeal spread is rare despite WHO Grade 1 - excellent prognosis after surgery

Pleomorphic Xanthoastrocytoma (PXA)

  • Young adults, temporal lobe
  • Classic: Cortically based, superficial, cyst + nodule; dural involvement/tail may be seen (but it's intra-axial!)
  • Can mimic meningioma due to dural contact
  • Often presents with chronic epilepsy
  • May dedifferentiate to anaplastic PXA (Grade 3) or GBM

Subependymal Giant Cell Astrocytoma (SEGA)

  • Virtually pathognomonic of tuberous sclerosis
  • Location: Foramen of Monro (causes obstructive hydrocephalus)
  • CT: Hyperdense, calcified; MRI: Heterogeneous with avid enhancement
  • Treatment: Surgical or mTOR inhibitor (everolimus)

8. EPENDYMOMAS

Key Facts

  • Arise from ependymal cells lining the ventricles and central canal
  • Bimodal distribution: Children (posterior fossa) and adults (spinal cord)
  • The WHO 2021 classification now defines ependymomas by molecular subtypes, not just location

Intracranial Ependymoma Locations

LocationAge GroupMolecular Subtype
4th ventricleChildrenPF-EPN-A or PF-EPN-B
SupratentorialOlder children/YAZFTA fusion-positive (formerly RELA)
SpinalAdultsNOS or myxopapillary

Imaging Features

  • 4th ventricle ependymoma: Classically "squeezing" through the foramina of Luschka/Magendie (plastic/insinuating growth) - high yield!
  • Heterogeneous: cysts, calcification, hemorrhage ("salt and pepper")
  • Moderate to marked enhancement
  • Leptomeningeal drop metastases occur - must image the whole spine

9. MEDULLOBLASTOMA

Epidemiology

  • Most common malignant brain tumor in children
  • Peak age 5-7 years; second peak in adults 20-40 years
  • Location: Cerebellar vermis (children, arising from 4th ventricle roof) vs. cerebellar hemisphere (adults)

WHO 2021 Molecular Subgroups (High Yield for Modern Practice)

SubgroupMolecular FeatureAgePrognosis
WNT-activatedCTNNB1 mutationOlder childrenBest (>90% survival)
SHH-activatedPTCH1, SMO, SUFUInfants + adultsIntermediate
Group 3MYC amplificationYoung childrenWorst
Group 4CDK6 amplificationAll agesIntermediate

Imaging Features

  • CT: Hyperdense vermian mass (highly cellular - high nuclear:cytoplasmic ratio causes T2 hypointensity and CT hyperdensity)
  • MRI T2: Isointense to hypointense - differentiates from pilocytic astrocytoma (T2 bright)
  • DWI: Markedly restricted diffusion (ADC very low) - key feature
  • Heterogeneous enhancement
  • Obstructive hydrocephalus common
  • Drop metastases along the spinal axis in ~30-40% - MRI whole spine mandatory at staging

10. BRAIN METASTASES - A RADIOLOGIST'S DAILY BREAD

Epidemiology

  • 10x more common than primary brain tumors in adults
  • Most common in adults >40 years
  • Common primaries: Lung (most common, ~50%), Breast, Melanoma, Renal cell, Colorectal

Distribution Pattern

  • 80% supratentorial (proportional to blood flow)
  • Predilection for gray-white matter junction (embolic trapping at small vessel branching)
  • 15% infratentorial (cerebellum)

Imaging Features

CT: Hypo/isodense mass + ring or solid enhancement + surrounding edema
MRI:
  • T1: Hypointense (or hyperintense if melanoma/hemorrhage)
  • T2: Hypointense to isointense solid portions; extensive surrounding vasogenic edema (often disproportionately large edema relative to the small metastatic nodule)
  • T1+Gd: Ring or solid enhancement; small metastases may be invisible without contrast - always use Gd-enhanced MRI
  • DWI: Variable (usually no restriction, unlike abscess which restricts)
  • SWI: Look for blooming artifact - melanoma, choriocarcinoma, thyroid metastases are hemorrhage-prone

Special Cases - High Yield for Radiology

Primary TumorSpecial Imaging Clue
MelanomaT1 hyperintense (melanin/hemorrhage); hemorrhagic
LungMost common; solitary or multiple
Renal cell carcinomaHypervascular, cystic, hemorrhagic
BreastLeptomeningeal spread common
ChoriocarcinomaHighly hemorrhagic

Solitary Metastasis vs. GBM - The Classic Differential

FeatureMetastasisGBM
LocationGM-WM junctionDeep white matter/basal ganglia
EdemaVasogenic, largeInfiltrative T2 halo
EnhancementClean ring/solidIrregular, nodular rim
MultiplicityOften multipleUsually solitary
ADC inner cavityUnrestrictedMay show restricted areas in necrotic core
MRSElevated Cho (if solid)Cho/NAA markedly elevated + lipid/lactate

11. PRIMARY CNS LYMPHOMA (PCNSL)

Overview

  • B-cell NHL confined to the CNS (usually diffuse large B-cell)
  • Increasing incidence in immunocompetent patients (not just AIDS)
  • Highly aggressive but steroid-sensitive and chemosensitive (HD-MTX based)

Imaging Features - "The Ghost Tumor"

  • Location: Deep gray matter (basal ganglia, thalamus), periventricular white matter, corpus callosum
  • CT: Hyperdense (due to high cellular density, nuclear:cytoplasm ratio)
  • MRI T2: Iso to hypointense (unlike most tumors - this is a key teaching point)
  • T1+Gd: Homogeneous, avid enhancement in immunocompetent patients
  • DWI: Markedly restricted diffusion (ADC very low) - due to hypercellularity
  • Immunocompromised patients (HIV/AIDS): Ring-enhancing; must differentiate from toxoplasmosis (toxo responds to empirical treatment; PCNSL does not)

The Ghost Tumor Sign

When steroids are given empirically before biopsy, PCNSL can literally disappear on MRI within days. This is pathognomonic - "the ghost tumor." Always avoid steroids before biopsy unless there is life-threatening herniation.
PCNSL and other CNS lymphoproliferative disease: Periventricular and multifocal enhancing masses in PCNSL; comparison with GBM, metastasis, and meningioma

12. GLIONEURONAL TUMORS

Ganglioglioma

  • Most common cause of chronic temporal lobe epilepsy in young patients
  • Location: Temporal lobe (>70%)
  • MRI: Cortically based, cyst + enhancing nodule (similar to pilocytic)
  • Calcification frequent
  • Usually Grade 1-2, excellent prognosis after surgery

DNET (Dysembryoplastic Neuroepithelial Tumor)

  • Young patients, intractable partial seizures
  • Supratentorial cortex (temporal, frontal)
  • "Bubbly" multicystic appearance - T1 hypointense, T2 bright
  • Classic: No edema, no mass effect, no enhancement (in most cases)
  • Cortical location, may have pseudogyral expansion

13. INTRAVENTRICULAR TUMORS (Technically Intra-Axial or Periventricular)

TumorAgeLocationKey Feature
Central neurocytomaYoung adultLateral ventricles, septum pellucidum"Bubbly," calcified, heterogeneous enhancing
SubependymomaMiddle-aged adults4th ventricle, lateral ventriclesNon-enhancing, very indolent
Choroid plexus papillomaChildren (<5 yrs)Lateral ventricle trigoneCauliflower, intense enhancement, hydrocephalus
EpendymomaChildren4th ventricleSqueezes through foramina
SEGAChildren/adolescentsForamen of MonroTuberous sclerosis
Colloid cystMiddle-agedForamen of MonroHyperdense CT; blocks CSF → acute hydrocephalus

14. ADVANCED MRI TECHNIQUES IN BRAIN TUMOR IMAGING

This section is what elevates a radiology seminar:

A. Diffusion-Weighted Imaging (DWI) / ADC

  • Low ADC (restricted diffusion) = high cellularity = high grade
  • Clinically key differentials:
    • Ring-enhancing lesion + restricted center → Abscess (pus restricts)
    • Ring-enhancing lesion + non-restricted center → GBM/metastasis (necrotic core = unrestricted)
    • Solid homogeneous lesion + markedly restricted → PCNSL (hypercellular)

B. Perfusion MRI (DSC, DCE, ASL)

  • DSC (Dynamic Susceptibility Contrast) - T2 perfusion*: Most validated; gives rCBV
    • rCBV >1.75 → High grade glioma (sensitivity 95%)
    • rCBV elevated in oligodendroglioma despite low grade (chicken-wire vasculature)
    • rCBV low → PCNSL, metastasis (despite enhancement), radiation necrosis
  • DCE (Dynamic Contrast-Enhanced) - T1 perfusion: Gives Ktrans, Ve (vessel permeability)
  • ASL (Arterial Spin Labeling): No contrast; good for pediatric patients

C. MR Spectroscopy (MRS)

MetaboliteSignificance
Choline (Cho)Membrane turnover; elevated in high-grade tumor
NAA (N-acetylaspartate)Neuronal marker; reduced in tumor
Creatine (Cr)Reference metabolite
Lipid/LactateNecrosis/anaerobic metabolism
2-HG peak at 2.25 ppmSpecific for IDH-mutant gliomas
  • Key ratios: Cho/NAA > 2 = malignant; Cho/NAA > 3 = highly malignant
  • MRS can detect tumor outside the enhancing margin

D. MR Perfusion + DWI + Spectroscopy Combined

Advanced MRI multiparametric imaging: DWI restriction, PWI elevated rCBF, MRS elevated Cho/NAA - epithelioid GBM example
Multiparametric MRI profile: (a) T2WI, (b) DWI with restricted diffusion, (c) CE T1 with dural tail sign (arrow), (d) ADC low signal, (e) PWI with elevated rCBF in red, (f) MRS showing elevated Cho and markedly reduced NAA

E. Tumor Microenvironment Mapping (Emerging)

Tumor Microenvironment comparison: GBM vs Metastasis vs PCNSL vs Meningioma - CE T1, FLAIR, O2 tension, neovascularization maps
Advanced TME mapping differentiating GBM (high hypoxia/necrosis), Metastasis (large necrotic center), PCNSL (dominant glycolysis, low hypoxia), and Meningioma (extra-axial, high OxPhos)

F. Radiogenomics / Radiomics

  • AI-based texture analysis can predict IDH status, MGMT methylation, 1p/19q codeletion non-invasively
  • T2/FLAIR mismatch sign: T2 homogeneous high signal WITH FLAIR isointense "mismatch" = highly specific for IDH-mutant, 1p/19q intact astrocytoma (specificity >90%)
  • Growing role in clinical practice and the 2021 WHO update has increased demand for radiomic biomarker integration

15. IMPORTANT DIFFERENTIAL DIAGNOSIS PEARLS

Ring-Enhancing Brain Lesion (RING)

CauseKey Clue
GlioblastomaIrregular ring, T2 halo, solitary, WM
Radiation necrosisPrevious RT history; MRS lipid/lactate no Cho
Infection (abscess)Thin smooth ring + DWI restricted center + fever
Neoplasm (metastasis)GM-WM junction, multiple, known primary
Granuloma (TB/Toxo)Smooth ring; contact history; HIV status
Demyelination (tumefactive MS)Open ring (horseshoe) enhancement; white matter lesions elsewhere; young woman

T2/FLAIR Mismatch Sign (High Yield)

  • T2 bright + FLAIR relatively dark/isointense within the same lesion
  • Specificity >90% for IDH-mutant, non-codeleted astrocytoma
  • Easy to use, no contrast needed

Corpus Callosum Involvement

Bilateral CC lesionDiagnosis
"Butterfly" mass, heterogeneousGBM
Periventricular, homogeneous, restricted DWIPCNSL
Multiple ovoid lesionsTumefactive MS (Dawson fingers)
Bilateral thalamic involvementDiffuse midline glioma

16. PEDIATRIC vs. ADULT BRAIN TUMORS - KEY DIFFERENCES

FeatureChildrenAdults
Most common locationPosterior fossa (infratentorial)Supratentorial
Most common tumorPilocytic astrocytomaGlioblastoma
Most common malignantMedulloblastomaGlioblastoma
Common entitiesDIPG, ependymoma, ATRTGBM, metastases, PCNSL
Molecular classificationNow critical (WHO 2021)IDH, MGMT, 1p/19q

17. IMAGING PROTOCOL RECOMMENDATION (For Your Department)

Standard Brain Tumor MRI Protocol:

  1. T1 3D (pre-contrast) - Anatomy baseline
  2. T2 Axial - Tumor delineation
  3. FLAIR Axial - Perilesional edema/infiltration
  4. DWI - Cellularity, abscess vs. tumor
  5. SWI/GRE - Hemorrhage, calcification, vessels
  6. T1+Gd 3D - Enhancement pattern (axial, coronal, sagittal)
  7. DSC Perfusion - rCBV for grading
  8. MRS (single or multivoxel) - Metabolite profile
Advanced/Research additions: DCE perfusion, ASL, DTI, fMRI (pre-surgical), sodium MRI, CEST, PET (FET, FDG, FDOPA)

18. TREATMENT RESPONSE CRITERIA - RANO

The Response Assessment in Neuro-Oncology (RANO) working group criteria incorporate:
  • Bidirectional enhancement measurements
  • Non-enhancing T2/FLAIR changes
  • Treatment timing context (pseudoprogression window = first 12 weeks post-RT)
  • Modified RANO-HGG for high-grade, RANO-LGG for low-grade
Volumetric imaging is increasingly favored over 2D bidirectional measurements for more accurate serial comparisons.

19. SUMMARY TABLE - INTRA-AXIAL TUMOR AT A GLANCE

TumorAgeLocationCTT2EnhancementDWIrCBVKey Feature
GBM55-75WM/deepHypodense+ringHeterogeneousIrregular ring+ restrictedHighNecrosis, T2 halo with tumor
Astrocytoma IDH-mut30-40Frontal WMHypodenseHomogeneous brightNone/faint-Low-modT2/FLAIR mismatch
Oligodendroglioma35-45Frontal cortexCalcifiedHeterogeneousVariable-ElevatedCalcification + cortical
Pilocytic<20CerebellumCyst+noduleCyst T2 brightNodule avid-LowCyst+nodule pattern
DNET<30Temporal cortexHypodenseBubbly brightNone-LowNo edema, no mass effect
Medulloblastoma5-7Vermis/4th VHyperdenseIso/hypointenseModerateModVery restrictedDrop mets, hyperdense CT
Ependymoma5-104th ventricleCalcifiedHeterogeneousModerate-LowSqueezes through foramina
PCNSL50-70BG/periventriculHyperdenseIso/hypointenseHomogeneous++ restrictedLow-modGhost sign, steroids
Metastasis>40GM-WM junctionVariableVasogenic edemaRing/solid- (center)VariableMultiple, known primary
GCT/Ganglioglioma10-30TemporalCalcifiedHeterogeneousVariableLowLowChronic epilepsy

20. EXTRA TOPICS TO INCLUDE IN YOUR SEMINAR

A. Leptomeningeal Disease

  • Tumors that spread via CSF: Medulloblastoma, ependymoma, GBM (rare), PCNSL, breast/lung mets
  • MRI: Leptomeningeal enhancement on post-Gd T1 FLAIR sequence
  • Post-Gd FLAIR is more sensitive than post-Gd T1 for leptomeningeal mets

B. Stereotactic Biopsy Targeting

  • Avoid the necrotic center - biopsy the enhancing rim or highest rCBV area
  • Perfusion-guided biopsy improves diagnostic yield

C. Post-Treatment Imaging Challenges

  • Pseudoprogression vs. true progression: MRS (low Cho = necrosis, high Cho = tumor), DSC perfusion (low rCBV = treatment effect)
  • LITT (Laser Interstitial Thermal Therapy): New ablative technique; post-treatment MRI shows a "treatment zone" with rim enhancement and central necrosis - recent AJNR review (2025) covers what the neuroradiologist should know

D. Functional Imaging for Pre-Surgical Planning

E. PET Imaging in Brain Tumors

  • FDG-PET: Limited due to high background glucose uptake in brain
  • FET-PET (fluoroethyl-tyrosine): Amino acid PET - excellent for tumor delineation, recurrence vs. necrosis
  • FDOPA-PET: Best for differentiating recurrence from treatment effects; note carbidopa effect on background
  • PET/MRI fusion gives best of both worlds

KEY TAKE-HOME MESSAGES FOR YOUR SEMINAR

  1. WHO 2021 changed everything - molecular markers are now primary, histology is secondary. Reports must mention IDH, 1p/19q, MGMT.
  2. Enhancement does NOT equal malignancy - 30-40% of GBMs may not enhance early; IDH-mutant Grade 2 gliomas rarely enhance. - Grainger & Allison's Diagnostic Radiology
  3. The T2/FLAIR halo of GBM always contains infiltrating tumor cells - surgical margins must extend beyond enhancement.
  4. T2/FLAIR mismatch sign = IDH-mutant non-codeleted astrocytoma with >90% specificity.
  5. PCNSL disappears with steroids - the "ghost tumor" - never give steroids before biopsy.
  6. DWI is your grading tool: PCNSL (most restricted) > Medulloblastoma > GBM solid areas > Low-grade glioma.
  7. rCBV > 1.75 = high grade (except oligodendroglioma which is falsely elevated).
  8. Medulloblastoma in the vermis + T2 hypointense + restricted DWI + drop mets = diagnosis.
  9. Gray-white matter junction + multiple lesions + vasogenic edema = Metastases until proven otherwise.
  10. Pseudoprogression and pseudoresponse are the radiologist's biggest challenge in neuro-oncology follow-up.
Sources: Grainger & Allison's Diagnostic Radiology (Textbook of Medical Imaging), Robbins & Kumar Basic Pathology, Goldman-Cecil Medicine 26E, Adams & Victor's Principles of Neurology 12E, Bradley & Daroff's Neurology in Clinical Practice; WHO CNS5 2021 Classification [PMC8328013]; AJNR WHO CNS5 Review; Radiopaedia WHO CNS Classification

Why not showing

Could you clarify what you mean by "not showing"? Are you referring to:
  1. The images not rendering/displaying in the previous response?
  2. A specific section or topic that was missing from the seminar content?
  3. Something else entirely?
If it's the images - they are embedded using markdown image syntax and should render in most interfaces. Some platforms (like plain text viewers or certain chat interfaces) may not render inline images. The images that were included were:
  • GBM MRI (T2, post-Gd T1, ADC) from Grainger & Allison's Radiology
  • IDH-wildtype astrocytoma MRI (4-panel: T2, T1+Gd, DWI, ADC)
  • Tumor microenvironment comparison (GBM vs Metastasis vs PCNSL vs Meningioma)
  • Multiparametric MRI profile (DWI, PWI, MRS)
  • PCNSL and CNS lymphoma comparison
If your interface supports image rendering, they should be visible. If not, let me know what platform you're using and I can suggest alternatives, or I can describe the images in more detail as diagrams/tables instead.

The details

Could you be more specific about which details are missing or not showing? For example:
  1. A specific tumor - e.g., "details about ependymoma are not enough" or "hemangioblastoma is missing"
  2. A specific section - e.g., "imaging protocol details," "pathology details," "treatment details"
  3. A specific aspect - e.g., "CT findings not detailed enough," "molecular markers not explained," "pediatric tumors section too brief"
  4. Something that was cut off - the response was very long; did it get truncated at a certain point?
Please let me know which part you feel is incomplete and I'll expand on it in full detail right away.

Expand imaging details (CT, MRI sequences, DWI/PWI/MRS findings) for each tumor type

Searching sources...
Finding Sources
Finding Sources
Searching Images

glioblastoma MRI T1 T2 FLAIR DWI ADC perfusion spectroscopy ring enhancement

Reading File
Reading File
Searching Images

medulloblastoma CT hyperdense posterior fossa DWI restricted diffusion

Educational multimodal composite illustrating an extra-axial variant of medulloblastoma in a pediatric patient. Section A (CT scan): Axial and sagittal unenhanced brain CT images reveal a well-defined hyperdense mass in the posterior fossa centered on the right cerebellopontine angle (CPA). White arrowheads indicate the 'cleft sign' (CSF fissure), confirming its extra-axial origin. Section B (MRI): Coronal T2-weighted and sagittal T1 post-contrast images demonstrate a sizeable, multilobulated mass exerting significant mass effect on the brainstem and middle cerebellar peduncle, leading to obstructive hydrocephalus (indicated by lateral ventricle dilation). DWI and ADC maps (c-d) confirm restricted diffusion within the mass. Section C (Histopathology): Hematoxylin and eosin (H&E) stained microscopy images show a highly cellular embryonal tumor. High-power magnification (b) reveals undifferentiated, small round cells with hyperchromatic nuclei and a fibrillary background of cellular processes, diagnostic of medulloblastoma. This case specifically represents the WNT-activated molecular subgroup.

Educational multimodal composite illustrating an extra-axial variant of medulloblastoma in a pediatric patient. Section A (CT scan): Axial and sagittal unenhanced brain CT images reveal a well-defined hyperdense mass in the posterior fossa centered on the right cerebellopontine angle (CPA). White arrowheads indicate the 'cleft sign' (CSF fissure), confirming its extra-axial origin. Section B (MRI): Coronal T2-weighted and sagittal T1 post-contrast images demonstrate a sizeable, multilobulated mass exerting significant mass effect on the brainstem and middle cerebellar peduncle, leading to obstructive hydrocephalus (indicated by lateral ventricle dilation). DWI and ADC maps (c-d) confirm restricted diffusion within the mass. Section C (Histopathology): Hematoxylin and eosin (H&E) stained microscopy images show a highly cellular embryonal tumor. High-power magnification (b) reveals undifferentiated, small round cells with hyperchromatic nuclei and a fibrillary background of cellular processes, diagnostic of medulloblastoma. This case specifically represents the WNT-activated molecular subgroup.

Reading File
Finding Sources
Searching Images

ependymoma fourth ventricle MRI heterogeneous enhancement foramina

**Imaging Modality:** Magnetic Resonance Imaging (MRI), Coronal view.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), Coronal view.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), T1-weighted sequence with gadolinium contrast enhancement.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), T1-weighted sequence with gadolinium contrast enhancement.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), Coronal plane.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), Coronal plane.

Reading File
Reading File
Loading Image
Reading File
Finding Sources
Searching Images

pilocytic astrocytoma cerebellum MRI cyst mural nodule enhancement

This diagnostic image set consists of two MRI scans demonstrating a pilocytic astrocytoma in the posterior fossa of a 26-year-old female. Image (a) is a sagittal T2-weighted MRI showing a large, well-circumscribed, hyperintense cystic mass located in the cerebellar vermis. A distinct, peripherally situated mural nodule (indicated by arrows) is visible on the posterior aspect of the cyst, which is causing significant mass effect and compression of the fourth ventricle. Image (b) is an axial contrast-enhanced T1-weighted MRI at the level of the cerebellum. It demonstrates the classic enhancement pattern of this pathology: the mural nodule (arrow) shows intense, homogeneous contrast uptake, and there is also smooth enhancement along the cyst wall (arrowheads). These features are hallmark diagnostic criteria for a WHO Grade I pilocytic astrocytoma. The clinical significance of these images lies in demonstrating the relationship between the cystic component, the enhancing solid nodule, and the resultant obstructive pressure on adjacent ventricular structures.

This diagnostic image set consists of two MRI scans demonstrating a pilocytic astrocytoma in the posterior fossa of a 26-year-old female. Image (a) is a sagittal T2-weighted MRI showing a large, well-circumscribed, hyperintense cystic mass located in the cerebellar vermis. A distinct, peripherally situated mural nodule (indicated by arrows) is visible on the posterior aspect of the cyst, which is causing significant mass effect and compression of the fourth ventricle. Image (b) is an axial contrast-enhanced T1-weighted MRI at the level of the cerebellum. It demonstrates the classic enhancement pattern of this pathology: the mural nodule (arrow) shows intense, homogeneous contrast uptake, and there is also smooth enhancement along the cyst wall (arrowheads). These features are hallmark diagnostic criteria for a WHO Grade I pilocytic astrocytoma. The clinical significance of these images lies in demonstrating the relationship between the cystic component, the enhancing solid nodule, and the resultant obstructive pressure on adjacent ventricular structures.

Sagittal gadolinium enhanced MRI of the brain in a 3 year old male demonstrates a large cystic lesion in the cerebellum with a conspicuously enhancing mural nodule. The mass is located in the posterior fossa, displacing adjacent cerebellar tissue and potentially affecting CSF pathways. The imaging signature, a cystic lesion with a solid, brightly enhancing mural nodule, is a classic pattern for pilocytic astrocytoma (juvenile pilocytic astrocytoma, JPA) in children. On T1 and T2 weighted sequences the cyst component typically shows low to intermediate signal with the mural nodule displaying solid enhancement after contrast administration. The border is well circumscribed, and peritumoral edema is minimal, reflecting a low grade glioma. Differential considerations include medulloblastoma and ependymoma, but age, tumor location, and the cyst plus nodule morphology strongly favor PA. Clinically, this pattern guides surgical planning toward maximal safe resection, which offers favorable prognosis in pediatric PA. Correlation with histology would reveal biphasic pilocytic architecture and Rosenthal fiber positive astrocytic cells. This case courtesy of Radiopaedia serves as an educational example of posterior fossa cystic neoplasms in children. Keywords: pediatric brain tumor, cerebellar tumor, posterior fossa, cystic lesion, enhancing mural nodule, gadolinium, MRI, prognosis, resection. Educationally relevant for learners and clinicians worldwide.

Sagittal gadolinium enhanced MRI of the brain in a 3 year old male demonstrates a large cystic lesion in the cerebellum with a conspicuously enhancing mural nodule. The mass is located in the posterior fossa, displacing adjacent cerebellar tissue and potentially affecting CSF pathways. The imaging signature, a cystic lesion with a solid, brightly enhancing mural nodule, is a classic pattern for pilocytic astrocytoma (juvenile pilocytic astrocytoma, JPA) in children. On T1 and T2 weighted sequences the cyst component typically shows low to intermediate signal with the mural nodule displaying solid enhancement after contrast administration. The border is well circumscribed, and peritumoral edema is minimal, reflecting a low grade glioma. Differential considerations include medulloblastoma and ependymoma, but age, tumor location, and the cyst plus nodule morphology strongly favor PA. Clinically, this pattern guides surgical planning toward maximal safe resection, which offers favorable prognosis in pediatric PA. Correlation with histology would reveal biphasic pilocytic architecture and Rosenthal fiber positive astrocytic cells. This case courtesy of Radiopaedia serves as an educational example of posterior fossa cystic neoplasms in children. Keywords: pediatric brain tumor, cerebellar tumor, posterior fossa, cystic lesion, enhancing mural nodule, gadolinium, MRI, prognosis, resection. Educationally relevant for learners and clinicians worldwide.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), T1-weighted axial sequence with gadolinium contrast enhancement.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), T1-weighted axial sequence with gadolinium contrast enhancement.

Finding Sources
Loading Image
Loading Image
Finding Sources
Searching Images

primary CNS lymphoma MRI DWI restricted diffusion periventricular homogeneous enhancement

Reading File
Finding Sources
Reading File
Loading Image
Reading File
Finding Sources
Here is the fully expanded imaging section for every major intra-axial brain tumor, with detailed CT, MRI sequence-by-sequence, DWI/PWI/MRS findings:

EXPANDED IMAGING DETAILS: INTRA-AXIAL BRAIN TUMORS

Sequence-by-Sequence Radiology Reference Guide

1. GLIOBLASTOMA (GBM, WHO Grade 4, IDH-wildtype)

CT

FindingDetail
UnenhancedLarge, heterogeneous hypodense mass in white matter
Hyperdense fociIntratumoral hemorrhage or highly cellular areas
CalcificationRare (<5%) - if present, suggests secondary GBM
EdemaProminent perilesional hypodensity (vasogenic)
Mass effectMidline shift, sulcal effacement, uncal herniation
EnhancementIrregular, thick, nodular ring enhancement

MRI - Sequence by Sequence

SequenceAppearance
T1 pre-GdHypointense mass with central dark necrotic core
T2Heterogeneous high signal; surrounding T2/FLAIR halo extends far beyond tumor
FLAIRThe surrounding high signal zone ALWAYS contains infiltrating tumor cells - not merely edema
T1+GdThick, irregular, nodular ring enhancement around a necrotic core; sometimes solid or multi-ring
SWI/GREBlooming/susceptibility artifact from microhemorrhage, necrotic debris
DWIRestricted diffusion (bright DWI, dark ADC) in hypercellular solid components and necrotic rim
ADC mapLow ADC in solid tumor rim; necrotic center shows unrestricted (high) ADC

Advanced MRI

PWI (DSC perfusion - rCBV):
  • Markedly elevated rCBV in the enhancing rim (typically >3-5x normal)
  • rCBV >1.75 cutoff: sensitivity 95% for high-grade glioma
  • Perfusion helps target biopsy to the highest-grade component
MRS:
  • Markedly elevated Cho (choline - membrane turnover)
  • Markedly reduced NAA (neuronal loss)
  • Cho/NAA ratio >3 = highly malignant
  • Prominent Lipid and Lactate peaks = necrosis + anaerobic metabolism
  • Key: MRS abnormality extends BEYOND the enhancing margin into T2 halo
fMRI/DTI:
  • Maps eloquent cortex (motor strip, Broca's/Wernicke's) relative to tumor
  • DTI shows CST displacement (resectable) vs. infiltration (higher surgical risk)
Imaging clue - "Butterfly GBM": Bilateral spread across corpus callosum. DDx: PCNSL, tumefactive MS, lymphoma.

2. IDH-WILDTYPE ASTROCYTOMA (WHO Grade 2-3, Non-GBM)

CT

  • Hypodense infiltrative mass, often without calcification
  • Variable or absent enhancement
  • Can look like a low-grade glioma - molecular testing required for diagnosis

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense, ill-defined
T2Heterogeneous high signal, ill-defined margins
FLAIRPersistent high signal (no mismatch - contrast with IDH-mutant astrocytoma)
T1+GdVariable - may show no enhancement even at Grade 3
DWILow-level restriction; may be subtly reduced ADC compared to IDH-mutant

Advanced MRI

  • rCBV: Elevated even without enhancement - reflects neovascularity
  • MRS: Elevated Cho, reduced NAA; absence of 2-HG peak (present in IDH-mutant)
  • Imaging biomarkers (multifocality, ill-defined margins, elevated perfusion) aid early identification

3. ASTROCYTOMA, IDH-MUTANT (Grade 2, 3, 4)

CT

  • Hypodense, cortical/subcortical location
  • Calcification uncommon
  • Grade 2: No enhancement; Grade 3: possible faint enhancement; Grade 4 (IDH-mutant GBM): ring enhancement

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense, well-defined
T2Homogeneous, markedly hyperintense - classic
FLAIRTHE KEY SIGN: Reduced/isointense FLAIR signal within markedly T2 hyperintense lesion = T2/FLAIR Mismatch Sign
T1+GdGrade 2: No enhancement (key feature); Grade 3: patchy/focal enhancement signals anaplastic transformation
DWINo significant restriction in low grade; restriction increases with grade
T2/FLAIR Mismatch Sign: T2 markedly hyperintense (A) with FLAIR isointense/hypointense core (B) in IDH-mutant 1p19q intact astrocytoma - Grainger & Allison's Radiology
T2/FLAIR Mismatch Sign: (A) T2 - markedly hyperintense mass; (B) FLAIR - paradoxically isointense/hypointense core. Specificity >90% for IDH-mutant, 1p/19q-intact astrocytoma.

Advanced MRI

PWI (rCBV): Lower than IDH-wt at equivalent grade; perfusion increases with anaplastic transformation MRS:
  • Elevated Cho, reduced NAA
  • 2-HG peak at 2.25 ppm: Specific for IDH-mutant tumors (detected on special MRS sequences at 3T)
  • No lipid/lactate at low grade Key: New enhancement in a previously non-enhancing IDH-mutant astrocytoma = malignant transformation

4. OLIGODENDROGLIOMA (IDH-mutant + 1p/19q codeleted, Grade 2-3)

CT

  • Cortically based hypodense mass, predominantly frontal lobe
  • Calcification in up to 90%: coarse, irregular, ribbon-like, or gyriform - best seen on CT
  • Patchy, irregular enhancement in ~20% of Grade 2; more common in Grade 3
  • Cysts present

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense; calcification may appear T1 hyperintense
T2Heterogeneous hyperintensity; involves cortex + subcortical WM
FLAIRHigh signal; cortical involvement prominent
SWI/GREBlooming artifact from calcification (T2 hypo + T1 hyper + SWI dark) - key feature
T1+GdVariable enhancement; lack of enhancement does NOT exclude Grade 3
DWIUsually no restriction in low grade; restriction suggests anaplasia

Advanced MRI

PWI (rCBV): Paradoxically elevated even in low-grade (Grade 2) oligodendroglioma - due to "chicken-wire" capillary architecture (branching finely vascularized stroma). This can falsely suggest malignancy - a high-yield teaching point.
MRS:
  • Elevated myo-inositol/glycine, glutamine, glutamate - hallmark of oligodendroglial elements
  • Where rCBV is non-specifically raised, MRS helps identify Grade 3 through lipid/lactate peaks
  • Cho/NAA elevated but less than GBM

5. DIFFUSE MIDLINE GLIOMA (H3 K27M-mutant, Grade 4)

CT

  • Diffuse, infiltrating, poorly defined hypo/isodense mass expanding the pons/thalamus
  • Enhancement variable or absent

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense, poorly defined, expands the structure (pons "engulfed")
T2Diffuse, high signal throughout affected structure
FLAIRDiffuse signal abnormality
T1+GdVariable: patchy, focal, or absent enhancement - enhancement does NOT indicate higher grade
DWI/ADCVariable; restricted areas suggest more aggressive foci

Advanced MRI

  • MRS: Elevated Cho/Cr; reduced NAA; Lipid/lactate in aggressive foci
  • Classic DIPG MRI: Diffuse pontine expansion, wraps around basilar artery, engulfs the pons, variable enhancement
Tip for DIPG: The diagnosis is CLINICAL + IMAGING. Biopsy is now increasingly performed for molecular profiling but was historically avoided due to location.

6. PILOCYTIC ASTROCYTOMA (WHO Grade 1)

CT

  • Well-circumscribed cystic or cyst-with-nodule mass
  • Cyst: hypodense; nodule: iso/hyperdense
  • Calcification in ~20%
  • Vivid enhancement of solid nodule

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense cyst; isointense mural nodule
T2Cyst: hyperintense (similar to CSF but slightly higher signal); Nodule: heterogeneous
FLAIRCyst: hypointense (unlike tumor); Nodule: high signal
T1+GdAvid, homogeneous enhancement of mural nodule only; cyst wall does NOT enhance
DWINo restriction in nodule (low grade)
Pilocytic Astrocytoma: Sagittal T2 - large cystic posterior fossa mass with mural nodule (arrows); Axial CE T1 - avid mural nodule enhancement (arrowheads) with enhancing cyst wall
Classic pilocytic astrocytoma: (a) Sagittal T2 - large cystic mass in cerebellar vermis with a peripherally situated mural nodule; (b) Axial CE T1 - intense homogeneous enhancement of the mural nodule with smooth cyst wall enhancement.

Advanced MRI

  • PWI (rCBV): Low - distinguishes from hemangioblastoma (which has very high rCBV despite similar appearance)
  • MRS: Mildly elevated Cho; reduced NAA; characteristic myoinositol peak; no lipid/lactate
  • Choline/NAA: Elevated but much less than malignant tumors
Key DDx: Pilocytic vs. Hemangioblastoma (in adults, posterior fossa): Both show cyst + nodule - use DSC perfusion: hemangioblastoma has markedly higher rCBV.

7. PLEOMORPHIC XANTHOASTROCYTOMA (PXA)

CT

  • Cortically based, often cystic, temporal lobe
  • Calcification in ~40%
  • Enhancement of solid component

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense solid component; cyst present in >50%
T2T2 hyperintense solid portion (despite xanthomatous/fatty nature, does NOT show T1 fat signal)
FLAIRHigh signal in solid component
T1+GdVivid enhancement of solid nodule; may show pseudodural tail - mimics meningioma
DWINo restriction at Grade 2

Advanced MRI

  • rCBV: Moderately elevated in solid component
  • MRS: Elevated Cho, reduced NAA; lipid/lactate in anaplastic variant
Teaching point: PXA can mimic meningioma (dural tail + avid enhancement + cortical location) but is truly intra-axial with cortical epicenter.

8. MEDULLOBLASTOMA (WHO Grade 4, Pediatric)

CT - Highly Characteristic

  • Hyperdense vermian mass (this CT hyperdensity is the most reliable early differentiator)
  • The hyperdensity reflects high nuclear:cytoplasmic ratio and densely packed cells
  • Cystic change, hemorrhage, and calcification frequently seen
  • Hydrocephalus common (obstructing 4th ventricle)
  • Enhancement: variable, patchy

MRI Sequence by Sequence

SequenceAppearance
T1Hypointense to isointense
T2Iso to hypointense relative to grey matter - key differentiator (compare: pilocytic = T2 bright)
FLAIRIsointense or mildly hyperintense
T1+GdModerate to avid heterogeneous enhancement
DWIMarkedly restricted diffusion - very high DWI signal, very low ADC - most reliable imaging feature
ADCADC value profoundly reduced (often among the lowest of all brain tumors)
Medulloblastoma: CT hyperdense posterior fossa mass (A,B) with CSF cleft confirming extra-axial variant; MRI coronal T2 (B-a), sagittal T1+Gd (B-b), DWI bright (B-c), ADC dark (B-d) - histology shows small round blue cells
Medulloblastoma: Upper panel (CT) - hyperdense posterior fossa mass with "cleft sign." Middle panel - coronal T2, sagittal T1+Gd with mass effect on brainstem; DWI bright (c) + ADC dark (d) = marked restriction. Lower panel - H&E histology showing densely packed small round blue cells.

Advanced MRI

MRS:
  • Reduced NAA (neuronal loss)
  • Elevated Cho/Cr ratio
  • Elevated taurine peak (relatively specific for medulloblastoma vs. other posterior fossa tumors)
  • Lactate and lipid peaks present
PWI: Moderate rCBV (less than GBM)
Full spine MRI mandatory: Drop metastases along spinal axis in ~30-40% at presentation; best seen on post-Gd T1 sagittal spine sequences.

9. EPENDYMOMA

CT

  • Iso to hyperdense 4th ventricular mass
  • Calcification in ~50% - punctate, peripheral
  • Hemorrhage in ~10%
  • Enhancement: moderate, heterogeneous

MRI Sequence by Sequence

SequenceAppearance
T1Heterogeneous iso/hypointense
T2Heterogeneous hyperintensity with mixed cystic, solid, hemorrhagic components ("salt and pepper")
FLAIRHigh signal; heterogeneous
T1+GdModerate, heterogeneous enhancement
DWIVariable, mild restriction (less than medulloblastoma)
SWIBlooming from calcification + microhemorrhage

The "Plastic/Toothpaste" Growth Pattern - High Yield

The most important imaging sign: ependymoma insinuates through the foramina of Luschka and Magendie, extending into the cerebellopontine angle cisterns and around the brainstem. This "squeezing through" behavior on sagittal/coronal MRI is pathognomonic.

Advanced MRI

  • MRS: Elevated Cho; reduced NAA; increased myoinositol
  • rCBV: Low to moderate
  • Spine MRI: Required at staging - leptomeningeal drop metastases occur in ~12%

10. PRIMARY CNS LYMPHOMA (PCNSL)

CT

  • Hyperdense (spontaneously) relative to white matter - reflects hypercellularity, high nuclear:cytoplasmic ratio
  • Periventricular, basal ganglia, or corpus callosum involvement
  • Homogeneous enhancement in immunocompetent; ring enhancement in immunocompromised

MRI Sequence by Sequence

SequenceAppearance
T1Isointense to hypointense
T2Isointense to hypointense - this is the KEY teaching point; most tumors are T2 bright, PCNSL is NOT
FLAIRPeriventricular high signal; mass often isointense
T1+GdHomogeneous, avid, "fluffy" enhancement in immunocompetent patients
DWIMarkedly restricted diffusion - ADC very low (second most restricted after medulloblastoma)
ADCVery low (<700 x10-6 mm²/s in most series)
SWIRarely hemorrhagic (unlike GBM) - absence of blooming helps
Histone H3K27M glioma (thalamic): T1 (A), T1+Gd (B), ADC map (C) - Grainger & Allison's Radiology
(Above: H3 K27M midline thalamic glioma for comparison - note: (A) T2 heterogeneous, (B) post-Gd variable enhancement in right thalamus, (C) ADC map showing restricted areas - contrasts with PCNSL pattern)

Advanced MRI

PWI (rCBV):
  • Low to moderate - paradoxically LOW for such an aggressively enhancing tumor
  • Mechanism: PCNSL lacks significant neovascularity/angiogenesis (unlike GBM)
  • This is a critical differentiator: Ring-enhancing lesion + restricted DWI + LOW rCBV = PCNSL
MRS:
  • Elevated Cho/Cr
  • Reduced NAA
  • Large lipid peak - characteristic; differentiates from toxoplasmosis (which lacks this)
  • Elevated lactate
The Ghost Tumor: Steroids before biopsy dissolve lymphomatous lesions within 24-72 hours, leaving no visible abnormality. Never give steroids before biopsy unless herniation is imminent.

11. BRAIN METASTASES

CT

  • Variable density; usually iso/hypodense
  • Hyperdense without contrast: melanoma, hemorrhagic mets (RCC, choriocarcinoma, thyroid)
  • Ring or solid enhancement - small mets may only show punctate enhancement
  • Disproportionately large vasogenic edema relative to small enhancing nodule - classic!
  • Location: Gray-white matter junction (embolic trapping at vessel caliber change)

MRI Sequence by Sequence

SequenceAppearance
T1 pre-GdUsually hypointense; T1 hyperintense: melanoma (melanin/hemorrhage), mucin-producing mets
T2Variable; surrounded by extensive vasogenic edema (finger-like, bright)
FLAIRExtensive surrounding edema; the lesion itself may be isointense
T1+GdRing (large mets) or solid (small mets) enhancement; multiple lesions should prompt metastasis search
SWIBlooming in hemorrhagic mets (melanoma, RCC, choriocarcinoma)
DWITypically no restriction in the central necrotic cavity (unrestricted - unlike abscess which restricts)
ADCHigh ADC in necrotic center; reduced in solid hypercellular areas

Advanced MRI

PWI (rCBV):
  • Elevated in solid tumor portions (hypervascular primaries like RCC = very high rCBV)
  • The rCBV drops sharply at the tumor-brain interface (unlike GBM which shows elevated rCBV in surrounding T2 halo)
MRS:
  • Elevated Cho in solid components
  • Reduced/absent NAA (no neurons within metastatic lesion)
  • Choline outside enhancing margin is absent - helps differentiate from GBM (which has elevated Cho even in non-enhancing T2 halo)
  • Lipid/lactate in necrotic areas
Key: GBM vs. Metastasis on MRS:
  • In GBM: Cho is elevated within the T2/FLAIR halo beyond the enhancement
  • In metastasis: Cho is normal in the surrounding edema - the edema is "pure" vasogenic edema without tumor infiltration

12. GANGLIOGLIOMA & DNET (Glioneuronal Tumors)

GANGLIOGLIOMA

CT:
  • Cortically based hypodense mass, temporal lobe predominance
  • Calcification in ~35-50%
  • Enhancement: variable nodular or peripheral
MRI:
SequenceAppearance
T1Hypointense; cyst component dark
T2Hyperintense solid and cystic components; mixed signal
FLAIRHigh signal
T1+GdVariable - peripheral or nodular enhancement in ~50%
DWINo restriction (low grade)
Advanced MRI:
  • rCBV: Low (Grade 1)
  • MRS: Mildly elevated Cho; reduced NAA

DNET (Dysembryoplastic Neuroepithelial Tumor)

CT:
  • Hypodense cortical mass, temporal or frontal
  • Calcification in ~25%
  • No mass effect, no edema
MRI:
SequenceAppearance
T1Hypointense cortical lesion
T2Bright, multicystic "bubbly" appearance - pseudomultiple cysts (micronodular)
FLAIRCortical high signal; characteristic peripheral hypointense rim (glial rim)
T1+GdUsually no enhancement - lack of enhancement in a young patient with epilepsy strongly suggests DNET
DWINo restriction
Classic imaging triad for DNET:
  1. Young patient with chronic partial seizures
  2. Cortical, bubbly T2 hyperintense mass
  3. No edema, no mass effect, no enhancement

13. HEMANGIOBLASTOMA (Common Adult Posterior Fossa Tumor)

Not a glial tumor but important intra-axial entity:

CT

  • Cystic mass with iso/hyperdense nodule (highly vascular)
  • Avid enhancement of solid nodule

MRI Sequence by Sequence

SequenceAppearance
T1Cyst dark; solid nodule iso/hypointense
T2Cyst bright; nodule with prominent flow voids (vascular channels)
FLAIRCyst: hypointense (near CSF signal)
T1+GdIntensely enhancing solid nodule; cyst wall does NOT enhance
DWINo restriction
MRA/SWIProminent internal vascularity, flow voids

Advanced MRI

  • rCBV: Very high - highest of the cyst+nodule tumors; far exceeds pilocytic astrocytoma
  • This is the key PWI differentiator: Hemangioblastoma (very high rCBV) vs. Pilocytic (low rCBV) - both show cyst+nodule pattern in posterior fossa
MRS: Non-specific; elevated Cho is mild
Association: Von Hippel-Lindau disease in ~20% - check for retinal angiomas, pancreatic cysts, renal cell carcinoma

MASTER COMPARISON TABLE: ADVANCED IMAGING PARAMETERS

TumorDWI RestrictionADCrCBVMRS Key FeaturesSWI
GBM+ (rim)Low rim; High coreVery High (>3)Cho↑↑, NAA↓↓, Lip/Lac↑↑Blooming (blood)
Astrocytoma IDH-mut-Normal/highLow-ModCho↑, NAA↓, 2-HG peakRare
Oligodendroglioma-NormalElevated (paradox)myo-inositol↑, Glu↑Blooming (calcification)
Pilocytic Astro-HighLowCho↑, NAA↓, myo-inositol↑Rare
DNET-HighLowNormal/mild Cho↑Rare
Medulloblastoma+++Very LowModerateNAA↓↓, Tau↑, Lac/Lip↑Rare
Ependymoma+/-Mildly lowLow-ModCho↑, myo-inositol↑Blooming (Ca++)
PCNSL++Very LowLow-ModCho↑↑, Lip↑↑, NAA↓↓No blooming
Metastasis- (center)High (center)ElevatedCho↑ (solid only); Normal haloVariable
Hemangioblastoma-HighVery HighMild Cho↑Flow voids
Ganglioglioma-NormalLowMild Cho↑, NAA↓Ca++ blooming
GBM IDH-wt+LowVery HighCho↑↑, NAA↓↓, 2-HG absentBlooming (blood)

QUICK-REFERENCE: DWI RESTRICTION LADDER (Most to Least)

MOST RESTRICTED
     |
     1. PCNSL (hypercellular lymphoma)
     2. Medulloblastoma (small round blue cells)
     3. GBM solid rim (hypercellular)
     4. Cerebral abscess (pus - viscous fluid)
     5. Epidermoid cyst (squamous debris)
     6. Ependymoma (mild)
     7. Low-grade glioma / metastasis necrotic core
     |
LEAST RESTRICTED

QUICK-REFERENCE: rCBV LADDER (Perfusion - Most to Least)

HIGHEST rCBV
     |
     1. Hemangioblastoma
     2. GBM / High-grade glioma
     3. Oligodendroglioma (paradoxically high for low grade)
     4. Brain metastasis (hypervascular primaries: RCC)
     5. PCNSL (surprisingly LOW despite enhancement)
     6. Pilocytic astrocytoma
     7. IDH-mutant low-grade astrocytoma
     8. DNET / Ganglioglioma
     |
LOWEST rCBV

POST-TREATMENT IMAGING: WHEN SEQUENCES LIE

PhenomenonTimingImagingKey Differentiator
PseudoprogressionWithin 12 weeks of RT+TMZNew/increasing enhancementMRS: lipid/lactate dominant, low Cho = treatment effect
PseudoresponseAnti-VEGF therapyDecrease in enhancement; tumor grows as T2/FLAIRFLAIR progression despite enhancement decrease
Radiation necrosis6+ months post-RTRing/solid enhancement, edemarCBV low; MRS: lipid/lactate but NO Cho; PET: FDG/FET hypometabolic
True progressionAny timeNew enhancing lesion beyond marginsrCBV high; Cho elevated; PET: hypermetabolic
MRS pearls for post-treatment:
  • Elevated Cho = active tumor
  • Elevated Lipid/Lactate with NO Cho = radiation necrosis
  • Intermediate pattern with BOTH = mixed response (most common)
Sources: Grainger & Allison's Diagnostic Radiology; Adams & Victor's Principles of Neurology 12E; Robbins & Kumar Basic Pathology; Goldman-Cecil Medicine 26E; WHO CNS5 Classification 2021 [PMC8328013]; AJNR 2023 WHO CNS5 newly recognized tumors review

Not showing

Could you clarify what specifically is "not showing"?
Option A - Images not rendering: The images I included are hosted URLs embedded in markdown (![alt](url)). If your interface doesn't render markdown images, they will appear as text/broken links. This is a platform/interface limitation, not a content issue.
Option B - Content/sections missing: Some part of the text details got cut off or truncated in your view.
Option C - Specific tumor not covered: A particular tumor type's imaging details were not included.
To help you right now regardless of interface:
Here are the direct image URLs you can open in any browser:
1. T2/FLAIR Mismatch Sign (IDH-mutant astrocytoma): https://cdn.orris.care/cdss_images/561d94f0b5f5c700026f3c8687e5bfd9f39898de0699a558f1584fd1fe3cd6e7.png
2. Classic GBM - T2, T1+Gd, ADC: https://cdn.orris.care/cdss_images/021e540005efca79912c3154bc37e48ca8b100aaefcf5892dd6b5e20fd3901fa.png
3. Pilocytic Astrocytoma - cyst + mural nodule: https://cdn.orris.care/cdss_images/pmc_clinical_VQA_25925ee83d829bc1aa8ea84ae2ff7d26305fd2d212197dcffd1c5c3953722597.jpg
4. Medulloblastoma - CT, MRI, DWI, histology: https://cdn.orris.care/cdss_images/pmc_clinical_VQA_419dd276fc104c4b2cca7ceb9ad62b152b85c35e2b2cd10d9dd8d310e263e106.jpg
5. H3 K27M thalamic glioma - T2, T1+Gd, ADC: https://cdn.orris.care/cdss_images/5db20ebd78732f9c63a61f8f029f78ff6658c7733d82ae6abae3c2ef306aed82.png
6. GBM multiparametric - DWI, PWI, MRS: https://cdn.orris.care/cdss_images/pmc_clinical_VQA_50e0e843de52fee72bdcd3be6af0cafbbc6db3bbfe9cf624f47de5af95042a49.jpg
Please let me know which option (A, B, or C) applies so I can address it precisely.

No response

I'm here and responding! It seems my previous messages are reaching you.
Could you clarify what you mean by "No response"?
  • Did my last reply not load fully? - The response was very long; sometimes long responses get cut off on mobile or slow connections. Try scrolling up or refreshing.
  • Did a specific question of yours go unanswered? - Please re-ask it and I'll answer directly.
  • Is the chat interface not working properly? - Try refreshing the page and sending your message again.
  • Are you asking me to provide something new? - Please tell me what you need and I'll respond immediately.
I'm fully available - just let me know what you need!

Generate a PowerPoint presentation on intra-axial tumors with images

Reading File
Reading File
Running Command

ls /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace/intraaxial-pptx && echo "ready"

Running Command

mkdir -p /tmp/workspace/intraaxial-pptx && python /tmp/skills/shared/scripts/fetch_images.py \ "https://cdn.orris.care/cdss_images/021e540005efca79912c3154bc37e48ca8b100aaefcf5892dd6b5e20fd3901fa.png" \ "https://cdn.orris.care/cdss_images/561d94f0b5f5c700026f3c8687e5bfd9f39898de0699a558f1584fd1fe3cd6e7.png" \ "https://cdn.orris.care/cdss_images/01145b1bd0b4929fdd8dc1feba434bc259d1c9b2d1b179cce8d39fbb6a1984a6.png" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_25925ee83d829bc1aa8ea84ae2ff7d26305fd2d212197dcffd1c5c3953722597.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_419dd276fc104c4b2cca7ceb9ad62b152b85c35e2b2cd10d9dd8d310e263e106.jpg" \ "https://cdn.orris.care/cdss_images/5db20ebd78732f9c63a61f8f029f78ff6658c7733d82ae6abae3c2ef306aed82.png" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_5a15411c436e57ed7a5b607b0906e0606d86b2d676de8ad1f2ec3a42e699f771.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_50e0e843de52fee72bdcd3be6af0cafbbc6db3bbfe9cf624f47de5af95042a49.jpg" \ 2>&1 | python3 -c " import sys, json data = json.load(sys.stdin) for i, item in enumerate(data): b64 = item.get('base64','') err = item.get('error','') print(f'Image {i}: OK={bool(b64)}, len={len(b64)}, err={err[:60] if err else None}') "

All 8 images loaded. Now building the full PowerPoint:
Running Command

cat << 'PYEOF' > /tmp/workspace/intraaxial-pptx/build_pptx.py import json, subprocess, base64 from io import BytesIO from pptx import Presentation from pptx.util import Inches, Pt, Emu from pptx.dml.color import RGBColor from pptx.enum.text import PP_ALIGN, MSO_ANCHOR from pptx.util import Inches, Pt # ── Fetch images ────────────────────────────────────────────────────────────── URLS = [ "https://cdn.orris.care/cdss_images/021e540005efca79912c3154bc37e48ca8b100aaefcf5892dd6b5e20fd3901fa.png", # 0 GBM T2/T1Gd/ADC "https://cdn.orris.care/cdss_images/561d94f0b5f5c700026f3c8687e5bfd9f39898de0699a558f1584fd1fe3cd6e7.png", # 1 T2/FLAIR mismatch "https://cdn.orris.care/cdss_images/01145b1bd0b4929fdd8dc1feba434bc259d1c9b2d1b179cce8d39fbb6a1984a6.png", # 2 Oligodendroglioma CT+MRI "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_25925ee83d829bc1aa8ea84ae2ff7d26305fd2d212197dcffd1c5c3953722597.jpg", # 3 Pilocytic astrocytoma "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_419dd276fc104c4b2cca7ceb9ad62b152b85c35e2b2cd10d9dd8d310e263e106.jpg", # 4 Medulloblastoma "https://cdn.orris.care/cdss_images/5db20ebd78732f9c63a61f8f029f78ff6658c7733d82ae6abae3c2ef306aed82.png", # 5 H3K27M thalamic glioma "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_5a15411c436e57ed7a5b607b0906e0606d86b2d676de8ad1f2ec3a42e699f771.jpg", # 6 TME comparison GBM/mets/PCNSL/meningioma "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_50e0e843de52fee72bdcd3be6af0cafbbc6db3bbfe9cf624f47de5af95042a49.jpg", # 7 Multiparametric MRI ] raw = subprocess.check_output(["python", "/tmp/skills/shared/scripts/fetch_images.py"] + URLS) imgs_data = json.loads(raw) imgs = [] for item in imgs_data: if item.get("base64"): imgs.append(BytesIO(base64.b64decode(item["base64"]))) else: imgs.append(None) # ── Helper constants ────────────────────────────────────────────────────────── W = Inches(13.333) H = Inches(7.5) # Color palette NAVY = RGBColor(0x1A, 0x3A, 0x5C) # dark blue BLUE = RGBColor(0x1E, 0x6E, 0xB5) # medium blue LTBLUE = RGBColor(0xD6, 0xE8, 0xF7) # light blue fill WHITE = RGBColor(0xFF, 0xFF, 0xFF) YELLOW = RGBColor(0xFF, 0xD7, 0x00) ORANGE = RGBColor(0xE8, 0x6C, 0x1A) GREEN = RGBColor(0x1A, 0x7A, 0x3C) GRAY = RGBColor(0x55, 0x55, 0x55) LGRAY = RGBColor(0xF0, 0xF4, 0xF8) prs = Presentation() prs.slide_width = W prs.slide_height = H blank = prs.slide_layouts[6] # ── Utility functions ───────────────────────────────────────────────────────── def add_rect(slide, x, y, w, h, fill_rgb=None, line_rgb=None, line_width=Pt(0)): shape = slide.shapes.add_shape(1, x, y, w, h) # MSO_SHAPE_TYPE.RECTANGLE = 1 shape.line.width = line_width if fill_rgb: shape.fill.solid() shape.fill.fore_color.rgb = fill_rgb else: shape.fill.background() if line_rgb: shape.line.color.rgb = line_rgb else: shape.line.fill.background() return shape def add_text(slide, text, x, y, w, h, size=Pt(18), bold=False, color=WHITE, align=PP_ALIGN.LEFT, wrap=True, italic=False): tb = slide.shapes.add_textbox(x, y, w, h) tf = tb.text_frame tf.word_wrap = wrap tf.margin_left = Inches(0.05) tf.margin_right = Inches(0.05) tf.margin_top = Inches(0.03) tf.margin_bottom = Inches(0.03) p = tf.paragraphs[0] p.alignment = align run = p.add_run() run.text = text run.font.size = size run.font.bold = bold run.font.italic = italic run.font.color.rgb = color run.font.name = "Calibri" return tb def add_multiline(slide, lines, x, y, w, h, size=Pt(14), color=WHITE, bold_first=False): """lines: list of (text, bold, color_override)""" tb = slide.shapes.add_textbox(x, y, w, h) tf = tb.text_frame tf.word_wrap = True tf.margin_left = Inches(0.08) tf.margin_right = Inches(0.05) tf.margin_top = Inches(0.05) tf.margin_bottom = Inches(0.03) first = True for (txt, bold, col) in lines: if first: p = tf.paragraphs[0] first = False else: p = tf.add_paragraph() p.space_before = Pt(2) run = p.add_run() run.text = txt run.font.size = size run.font.bold = bold run.font.color.rgb = col if col else color run.font.name = "Calibri" return tb def add_image(slide, img_io, x, y, w, h): if img_io is None: return img_io.seek(0) slide.shapes.add_picture(img_io, x, y, w, h) def header_bar(slide, title, subtitle=None): add_rect(slide, 0, 0, W, Inches(1.1), fill_rgb=NAVY) add_text(slide, title, Inches(0.3), Inches(0.08), Inches(10), Inches(0.6), size=Pt(28), bold=True, color=WHITE) if subtitle: add_text(slide, subtitle, Inches(0.3), Inches(0.65), Inches(12), Inches(0.4), size=Pt(14), bold=False, color=LTBLUE) # accent line add_rect(slide, 0, Inches(1.1), W, Inches(0.06), fill_rgb=BLUE) def footer_bar(slide, note="Grainger & Allison's Diagnostic Radiology | WHO CNS5 2021"): add_rect(slide, 0, Inches(7.2), W, Inches(0.3), fill_rgb=NAVY) add_text(slide, note, Inches(0.3), Inches(7.2), Inches(12), Inches(0.3), size=Pt(9), color=LTBLUE, align=PP_ALIGN.LEFT) def bg(slide): add_rect(slide, 0, 0, W, H, fill_rgb=LGRAY) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 1 – TITLE SLIDE # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) add_rect(slide, 0, 0, W, H, fill_rgb=NAVY) add_rect(slide, 0, Inches(2.8), W, Inches(2.4), fill_rgb=BLUE) add_text(slide, "INTRA-AXIAL BRAIN TUMORS", Inches(0.5), Inches(1.1), Inches(12), Inches(1.1), size=Pt(44), bold=True, color=WHITE, align=PP_ALIGN.CENTER) add_text(slide, "A Comprehensive Radiology Seminar", Inches(0.5), Inches(2.2), Inches(12), Inches(0.6), size=Pt(22), bold=False, color=YELLOW, align=PP_ALIGN.CENTER) add_text(slide, "Classification | CT & MRI Imaging | Advanced Techniques | Differentials", Inches(0.5), Inches(2.95), Inches(12), Inches(0.55), size=Pt(16), bold=False, color=WHITE, align=PP_ALIGN.CENTER) bullets = [ "WHO CNS5 (2021) Classification", "Gliomas: GBM, IDH-mutant, Oligodendroglioma", "Embryonal Tumors: Medulloblastoma", "Metastases & Primary CNS Lymphoma", "Advanced MRI: DWI / PWI / MRS", ] for i, b in enumerate(bullets): add_text(slide, f"▸ {b}", Inches(3.5), Inches(3.75 + i*0.5), Inches(8.5), Inches(0.45), size=Pt(15), color=LTBLUE) add_text(slide, "For Radiology Residents | August 2026", Inches(0.5), Inches(7.0), Inches(12), Inches(0.35), size=Pt(12), color=YELLOW, align=PP_ALIGN.CENTER) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 2 – DEFINITION & CLASSIFICATION # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Definition & Classification", "What Are Intra-Axial Tumors?") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(6.1), Inches(5.75), fill_rgb=NAVY) add_rect(slide, Inches(6.5), Inches(1.25), Inches(6.6), Inches(5.75), fill_rgb=WHITE, line_rgb=BLUE, line_width=Pt(1.5)) add_text(slide, "DEFINITION", Inches(0.3), Inches(1.3), Inches(5.8), Inches(0.45), size=Pt(16), bold=True, color=YELLOW) defn = [ ("Tumors arising from WITHIN the brain parenchyma", True, WHITE), ("Origin: neurons, glial cells, ependymal lining, primitive cells", False, LTBLUE), ("", False, None), ("✦ Contrast: Extra-axial tumors (meningioma, schwannoma)\n compress brain from outside", False, LTBLUE), ("", False, None), ("RADIOLOGICAL SIGNS OF INTRA-AXIAL ORIGIN:", True, YELLOW), ("▸ No CSF cleft between lesion and brain", False, WHITE), ("▸ No buckling/displacement of gray-white interface", False, WHITE), ("▸ No broad dural base", False, WHITE), ("▸ Epicenter WITHIN brain parenchyma", False, WHITE), ("▸ Surrounding infiltrative edema", False, WHITE), ] add_multiline(slide, defn, Inches(0.3), Inches(1.75), Inches(5.8), Inches(4.8), size=Pt(13)) add_text(slide, "WHO CNS5 (2021) MAJOR CATEGORIES", Inches(6.6), Inches(1.3), Inches(6.2), Inches(0.45), size=Pt(14), bold=True, color=NAVY) categories = [ ("1. Diffuse Glial Tumors", BLUE, True), (" GBM · IDH-mutant Astrocytoma · Oligodendroglioma", GRAY, False), ("2. Circumscribed Gliomas", BLUE, True), (" Pilocytic · PXA · SEGA", GRAY, False), ("3. Glioneuronal Tumors", BLUE, True), (" Ganglioglioma · DNET · Central Neurocytoma", GRAY, False), ("4. Ependymal Tumors", BLUE, True), (" Ependymoma · Subependymoma", GRAY, False), ("5. Embryonal Tumors (Pediatric)", BLUE, True), (" Medulloblastoma · ATRT", GRAY, False), ("6. Non-primary Intra-Axial", BLUE, True), (" Metastases · PCNSL", GRAY, False), ] for i, (txt, col, bold) in enumerate(categories): add_text(slide, txt, Inches(6.6), Inches(1.85 + i*0.34), Inches(6.2), Inches(0.38), size=Pt(12), bold=bold, color=col) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 3 – GBM IMAGING # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Glioblastoma (GBM) – WHO Grade 4, IDH-Wildtype", "Most Common Primary Malignant Brain Tumor in Adults | Median Survival 12-14 months") footer_bar(slide) # Left panel – key facts add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "KEY FACTS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) facts = [ ("Peak Age: 55-75 years", False, WHITE), ("IDH-wildtype (>90% primary)", False, LTBLUE), ("MGMT methylation → better TMZ response", False, LTBLUE), ("", False, None), ("CT FINDINGS:", True, YELLOW), ("▸ Hypodense mass, WM-based", False, WHITE), ("▸ Irregular ring enhancement", False, WHITE), ("▸ Central necrosis (hypodense)", False, WHITE), ("▸ Vasogenic edema + mass effect", False, WHITE), ("▸ Calcification rare (<5%)", False, WHITE), ("", False, None), ("MRI FINDINGS:", True, YELLOW), ("▸ T1: heterogeneous, dark necrotic core", False, WHITE), ("▸ T2/FLAIR: extensive halo (CONTAINS TUMOR)", False, ORANGE), ("▸ T1+Gd: thick irregular RING enhancement", False, WHITE), ("▸ DWI: restricted in solid rim", False, WHITE), ("▸ SWI: blooming from hemorrhage", False, WHITE), ("", False, None), ("ADVANCED MRI:", True, YELLOW), ("▸ rCBV markedly elevated (>3-5×)", False, WHITE), ("▸ MRS: Cho↑↑ NAA↓↓ Lip/Lac↑↑", False, WHITE), ("▸ Cho/NAA ratio >3", False, WHITE), ] add_multiline(slide, facts, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.0), size=Pt(11.5)) # Right: image if imgs[0]: imgs[0].seek(0) add_image(slide, imgs[0], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: GBM – (A) T2: heterogeneous mass + vasogenic edema (B) T1+Gd: ring enhancement (C) ADC: restricted diffusion in solid rim", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 4 – IDH-MUTANT ASTROCYTOMA + T2/FLAIR MISMATCH # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Astrocytoma, IDH-Mutant (Grade 2-4)", "T2/FLAIR Mismatch Sign | Specificity >90% for IDH-mutant 1p/19q Intact") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) astro = [ ("Age: 30-40 years | Frontal/temporal WM", False, LTBLUE), ("Survival: ~6 years (IDH-mutant)", False, LTBLUE), ("", False, None), ("CT:", True, YELLOW), ("▸ Hypodense, subcortical location", False, WHITE), ("▸ No/faint enhancement at Grade 2", False, WHITE), ("▸ Calcification uncommon", False, WHITE), ("", False, None), ("MRI SEQUENCE-BY-SEQUENCE:", True, YELLOW), ("▸ T1: hypointense, well-defined", False, WHITE), ("▸ T2: MARKEDLY hyperintense (homogeneous)", False, WHITE), ("▸ FLAIR: KEY SIGN BELOW ↓", False, ORANGE), ("▸ T1+Gd: NO enhancement (Grade 2)", False, WHITE), ("▸ Enhancement = malignant transformation!", False, ORANGE), ("▸ DWI: no restriction (low grade)", False, WHITE), ("", False, None), ("T2/FLAIR MISMATCH SIGN:", True, YELLOW), ("T2 = markedly hyperintense", False, WHITE), ("FLAIR = paradoxically iso/hypointense", False, WHITE), ("→ Specificity >90% for IDH-mut 1p19q intact", False, ORANGE), ("→ Present in ~50% of patients", False, WHITE), ("", False, None), ("ADVANCED MRI:", True, YELLOW), ("▸ rCBV: LOW (increases with grade)", False, WHITE), ("▸ MRS: Cho↑, NAA↓, 2-HG peak @ 2.25 ppm", False, WHITE), ("▸ No Lip/Lac at low grade", False, WHITE), ] add_multiline(slide, astro, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(11)) if imgs[1]: imgs[1].seek(0) add_image(slide, imgs[1], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: T2/FLAIR Mismatch Sign – (A) T2: markedly hyperintense mass (B) FLAIR: paradoxically isointense core | WHO Grade II IDH-mutant 1p19q-intact astrocytoma", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 5 – OLIGODENDROGLIOMA # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Oligodendroglioma – IDH-mutant + 1p/19q Codeleted (Grade 2-3)", "Best Prognosis Among Diffuse Gliomas | Mean Survival ~8 Years") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) oligo = [ ("Age: 35-45 yrs | Frontal lobe cortex/subcortex", False, LTBLUE), ("Presents with chronic epilepsy", False, LTBLUE), ("", False, None), ("CT (Most Characteristic Modality):", True, YELLOW), ("▸ CALCIFICATION in up to 90%", False, ORANGE), ("▸ Coarse, irregular, ribbon-like calcification", False, WHITE), ("▸ Cortically based hypodense mass", False, WHITE), ("▸ Enhancement in ≥20% of Grade 2", False, WHITE), ("", False, None), ("MRI:", True, YELLOW), ("▸ T1: hypointense; Ca++ may be T1 bright", False, WHITE), ("▸ T2: heterogeneous, cortex + WM", False, WHITE), ("▸ SWI/GRE: BLOOMING from calcification", False, ORANGE), ("▸ T1+Gd: variable; no enhancement ≠ Grade 2", False, WHITE), ("▸ DWI: no restriction (low grade)", False, WHITE), ("", False, None), ("ADVANCED MRI – KEY TEACHING POINT:", True, YELLOW), ("▸ rCBV: ELEVATED even in Grade 2 (paradox!)", False, ORANGE), ("▸ 'Chicken-wire' vasculature → high rCBV", False, WHITE), ("▸ May falsely suggest high-grade glioma", False, WHITE), ("▸ MRS: myo-inositol↑, glutamine↑, glutamate↑", False, WHITE), ("▸ Lip/Lac peaks = anaplastic transformation", False, WHITE), ] add_multiline(slide, oligo, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(11)) if imgs[2]: imgs[2].seek(0) add_image(slide, imgs[2], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: Oligodendroglioma – CT: calcified frontal cortical mass (A,B) | T2 MRI (C): heterogeneous | T1+Gd (D): irregular enhancement after 2 years", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 6 – DIFFUSE MIDLINE GLIOMA / DIPG # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Diffuse Midline Glioma – H3 K27M-Mutant (WHO Grade 4)", "Includes DIPG | All Cases Grade 4 Regardless of Histology | Median Survival <12 months") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) dipg = [ ("Age: Children & adolescents (also adults >80y)", False, LTBLUE), ("Location: Pons (DIPG), thalamus, spinal cord", False, LTBLUE), ("", False, None), ("CT:", True, YELLOW), ("▸ Diffuse, poorly defined hypo/isodense", False, WHITE), ("▸ Expands the pons (T2 halo encases basilar a.)", False, WHITE), ("▸ Enhancement variable/absent", False, WHITE), ("", False, None), ("MRI:", True, YELLOW), ("▸ T1: hypointense, ill-defined, expands structure", False, WHITE), ("▸ T2: DIFFUSE high signal filling pons", False, WHITE), ("▸ FLAIR: diffuse signal abnormality", False, WHITE), ("▸ T1+Gd: variable - DOES NOT indicate grade", False, ORANGE), ("▸ DWI/ADC: variable, restriction in aggressive foci", False, WHITE), ("", False, None), ("CLASSIC DIPG PATTERN:", True, YELLOW), ("▸ Diffuse pontine expansion", False, WHITE), ("▸ Wraps around basilar artery (>50% of pons)", False, WHITE), ("▸ Engulfs the pons", False, WHITE), ("▸ Short symptom onset (<3 weeks in children)", False, WHITE), ("", False, None), ("ADVANCED MRI:", True, YELLOW), ("▸ MRS: Cho↑, NAA↓, Lac/Lip in aggressive areas", False, WHITE), ("▸ PWI: variable rCBV", False, WHITE), ("▸ Biopsy now performed for H3 K27M profiling", False, WHITE), ] add_multiline(slide, dipg, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(11)) if imgs[5]: imgs[5].seek(0) add_image(slide, imgs[5], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: H3 K27M-Mutant Glioma (Thalamic) – (A) T2: diffuse hyperintensity (B) T1+Gd: variable/focal enhancement (C) ADC: restricted areas in aggressive component", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 7 – PILOCYTIC ASTROCYTOMA # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Pilocytic Astrocytoma – WHO Grade 1", "Most Common Brain Tumor in Children | 10-Year Survival >90% | Cyst + Mural Nodule") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) pilo = [ ("Age: <20 yrs (children/young adults)", False, LTBLUE), ("Location: Cerebellum > optic pathway > hypothalamus", False, LTBLUE), ("", False, None), ("CT:", True, YELLOW), ("▸ Well-circumscribed cyst + hyperdense nodule", False, WHITE), ("▸ Calcification in ~20%", False, WHITE), ("▸ Vivid nodule enhancement", False, WHITE), ("", False, None), ("MRI – CLASSIC PATTERN:", True, YELLOW), ("▸ T1: hypointense cyst; isointense nodule", False, WHITE), ("▸ T2: cyst bright (↑ than CSF); nodule heterogeneous", False, WHITE), ("▸ FLAIR: cyst hypointense; nodule high signal", False, WHITE), ("▸ T1+Gd: AVID nodule enhancement", False, ORANGE), ("▸ CYST WALL DOES NOT ENHANCE", False, ORANGE), ("▸ DWI: NO restriction (low grade)", False, WHITE), ("", False, None), ("ADVANCED MRI:", True, YELLOW), ("▸ rCBV: LOW (key DDx from hemangioblastoma)", False, WHITE), ("▸ MRS: mild Cho↑, myo-inositol↑, NAA↓", False, WHITE), ("▸ No Lip/Lac", False, WHITE), ("", False, None), ("KEY DDx - POSTERIOR FOSSA CYST+NODULE:", True, YELLOW), ("Pilocytic (low rCBV) vs Hemangioblastoma", False, WHITE), ("(very high rCBV – use DSC perfusion to distinguish)", False, WHITE), ] add_multiline(slide, pilo, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(11)) if imgs[3]: imgs[3].seek(0) add_image(slide, imgs[3], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: Pilocytic Astrocytoma – (a) Sagittal T2: cystic mass with mural nodule (arrows) | (b) CE T1: intense nodule enhancement (arrowheads) with smooth cyst wall", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 8 – MEDULLOBLASTOMA # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Medulloblastoma – Most Common Malignant Brain Tumor in Children", "WHO Grade 4 | Cerebellar Vermis | CT Hyperdense + DWI Markedly Restricted") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) medullo = [ ("Age: Peak 5-7 yrs; 2nd peak 20-40 yrs (adult)", False, LTBLUE), ("Location: Vermis (children) | Hemisphere (adults)", False, LTBLUE), ("", False, None), ("CT – MOST CHARACTERISTIC:", True, YELLOW), ("▸ HYPERDENSE vermian mass (high NC ratio)", False, ORANGE), ("▸ Hydrocephalus from 4th ventricle obstruction", False, WHITE), ("▸ Cysts, hemorrhage, calcification seen", False, WHITE), ("▸ Patchy variable enhancement", False, WHITE), ("", False, None), ("MRI:", True, YELLOW), ("▸ T1: iso/hypointense", False, WHITE), ("▸ T2: ISO-TO-HYPOINTENSE (unlike pilocytic!)", False, ORANGE), ("▸ T1+Gd: moderate heterogeneous enhancement", False, WHITE), ("▸ DWI: MARKEDLY RESTRICTED (key feature)", False, ORANGE), ("▸ ADC: profoundly reduced (lowest of all tumors)", False, ORANGE), ("", False, None), ("MRS:", True, YELLOW), ("▸ NAA↓↓, Cho/Cr↑", False, WHITE), ("▸ TAURINE PEAK (relatively specific)", False, ORANGE), ("▸ Lactate + lipid peaks", False, WHITE), ("", False, None), ("MOLECULAR SUBGROUPS (WHO 2021):", True, YELLOW), ("▸ WNT-activated: best prognosis (>90% survival)", False, GREEN), ("▸ SHH-activated: intermediate", False, WHITE), ("▸ Group 3 (MYC amplification): WORST prognosis", False, ORANGE), ("▸ Group 4: intermediate", False, WHITE), ("", False, None), ("⚠ MANDATORY: Whole-spine MRI for drop mets (30-40%)", True, ORANGE), ] add_multiline(slide, medullo, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(10.5)) if imgs[4]: imgs[4].seek(0) add_image(slide, imgs[4], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: Medulloblastoma – CT hyperdense posterior fossa mass (A,B) | MRI T2 (B-a), T1+Gd (B-b) | DWI bright + ADC dark = marked restriction (B-c,d) | H&E: small round blue cells", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 9 – PRIMARY CNS LYMPHOMA # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Primary CNS Lymphoma (PCNSL)", "'The Ghost Tumor' | NEVER Give Steroids Before Biopsy | Steroid-Sensitive") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) pcnsl = [ ("Age: 50-70 yrs (immunocompetent) | AIDS/HIV", False, LTBLUE), ("Type: Diffuse Large B-Cell NHL", False, LTBLUE), ("Location: Periventricular, basal ganglia, CC", False, LTBLUE), ("", False, None), ("CT:", True, YELLOW), ("▸ HYPERDENSE spontaneously (high cellularity)", False, ORANGE), ("▸ Periventricular or BG location", False, WHITE), ("▸ Homogeneous enhancement (immunocompetent)", False, WHITE), ("▸ Ring enhancement (immunocompromised)", False, WHITE), ("", False, None), ("MRI – KEY TEACHING POINTS:", True, YELLOW), ("▸ T2: ISO-TO-HYPOINTENSE (most tumors are bright!)", False, ORANGE), ("▸ FLAIR: periventricular high signal", False, WHITE), ("▸ T1+Gd: HOMOGENEOUS 'fluffy' enhancement", False, WHITE), ("▸ DWI: MARKEDLY RESTRICTED", False, ORANGE), ("▸ ADC: very low (<700×10⁻⁶ mm²/s)", False, ORANGE), ("▸ SWI: NO blooming (rarely hemorrhagic – unlike GBM)", False, WHITE), ("", False, None), ("ADVANCED MRI – CRITICAL DDx CLUE:", True, YELLOW), ("▸ rCBV: LOW-TO-MODERATE (paradox!)", False, ORANGE), ("▸ Despite avid enhancement – lacks neovascularity", False, WHITE), ("▸ Ring-enhancing + restricted DWI + LOW rCBV = PCNSL", False, ORANGE), ("▸ MRS: Cho↑↑, Lip↑↑, NAA↓↓, large lipid peak", False, WHITE), ("", False, None), ("THE GHOST TUMOR:", True, YELLOW), ("Steroids → lesion disappears in 24-72 hours", False, WHITE), ("= Pathognomonic but prevents diagnosis!", False, ORANGE), ] add_multiline(slide, pcnsl, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(10.5)) if imgs[6]: imgs[6].seek(0) add_image(slide, imgs[6], Inches(4.85), Inches(1.3), Inches(8.2), Inches(4.5)) add_rect(slide, Inches(4.85), Inches(5.85), Inches(8.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: Tumor microenvironment comparison – Row C (PCNSL): CE T1 homogeneous enhancement, FLAIR, PO2 map, MTI map | Radar: dominant glycolysis (65%), minimal necrosis (7%)", Inches(4.9), Inches(5.87), Inches(8.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 10 – BRAIN METASTASES # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Brain Metastases", "10× More Common Than Primary Tumors | Gray-White Matter Junction | Always Use Gd-MRI") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(4.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "IMAGING FINDINGS", Inches(0.3), Inches(1.3), Inches(4.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) mets_facts = [ ("Common primaries: Lung (50%) > Breast > Melanoma", False, LTBLUE), ("Location: Gray-white matter junction (embolic)", False, LTBLUE), ("80% supratentorial | 15% cerebellum", False, LTBLUE), ("", False, None), ("CT:", True, YELLOW), ("▸ Variable density (iso/hypodense/hyperdense)", False, WHITE), ("▸ Hyperdense: melanoma, hemorrhagic mets", False, ORANGE), ("▸ Ring or solid enhancement", False, WHITE), ("▸ DISPROPORTIONATELY large vasogenic edema", False, ORANGE), ("▸ vs. small enhancing nodule (classic pattern)", False, WHITE), ("", False, None), ("MRI:", True, YELLOW), ("▸ T1: hypointense; T1 BRIGHT = melanoma/mucinous", False, WHITE), ("▸ T2: extensive surrounding vasogenic edema", False, WHITE), ("▸ T1+Gd: ring (large) or solid (small) enhancement", False, WHITE), ("▸ Small mets invisible WITHOUT contrast", False, ORANGE), ("▸ DWI: NO restriction in necrotic center", False, WHITE), ("▸ SWI: blooming in melanoma, RCC, choriocarcinoma", False, WHITE), ("", False, None), ("ADVANCED MRI:", True, YELLOW), ("▸ rCBV: elevated in solid portions", False, WHITE), ("▸ rCBV drops sharply at tumor-brain interface", False, WHITE), ("▸ MRS in surrounding halo: NORMAL Cho", False, ORANGE), ("▸ (GBM halo = elevated Cho – key differentiator)", False, ORANGE), ("", False, None), ("SPECIAL PRIMARY CLUES:", True, YELLOW), ("▸ Melanoma: T1 bright, hemorrhagic", False, WHITE), ("▸ RCC: hypervascular, cystic, hemorrhagic", False, WHITE), ("▸ Breast: leptomeningeal spread common", False, WHITE), ] add_multiline(slide, mets_facts, Inches(0.3), Inches(1.75), Inches(4.3), Inches(5.2), size=Pt(10.5)) # right panel: comparison table text (no image for this slide - use text layout) add_rect(slide, Inches(4.85), Inches(1.3), Inches(8.2), Inches(5.7), fill_rgb=WHITE, line_rgb=BLUE, line_width=Pt(1.5)) add_text(slide, "GBM vs. METASTASIS – Key Differentiators", Inches(5.0), Inches(1.4), Inches(7.8), Inches(0.4), size=Pt(15), bold=True, color=NAVY) headers = ["Feature", "GBM", "Metastasis"] widths = [Inches(2.2), Inches(2.8), Inches(3.0)] xs = [Inches(5.0), Inches(7.2), Inches(10.0)] row_h = Inches(0.38) rows = [ ("Location", "Deep WM / BG", "GM-WM junction"), ("Multiplicity", "Usually solitary", "Often multiple"), ("Edema", "Infiltrative T2 halo", "Vasogenic, large"), ("Enhancement", "Irregular ring", "Clean ring/solid"), ("DWI center", "Restricted (solid areas)", "Unrestricted (necrosis)"), ("MRS halo", "Cho ELEVATED", "Cho NORMAL"), ("rCBV halo", "Elevated (tumor infiltr.)", "Normal"), ("Gd protocol", "Ring + necrosis", "Ring/solid nodule"), ] for col_i, (hdr, x, w) in enumerate(zip(headers, xs, widths)): add_rect(slide, x, Inches(1.85), w, Inches(0.38), fill_rgb=NAVY) add_text(slide, hdr, x, Inches(1.86), w, Inches(0.36), size=Pt(12), bold=True, color=WHITE, align=PP_ALIGN.CENTER) for row_i, row in enumerate(rows): bg_col = LGRAY if row_i % 2 == 0 else WHITE for col_i, (val, x, w) in enumerate(zip(row, xs, widths)): add_rect(slide, x, Inches(2.23 + row_i * row_h), w, row_h, fill_rgb=bg_col, line_rgb=BLUE, line_width=Pt(0.5)) col_color = NAVY if col_i == 0 else (ORANGE if "Elevated" in val or "ELEVATED" in val else GRAY) add_text(slide, val, x, Inches(2.24 + row_i * row_h), w, Inches(0.36), size=Pt(11), color=col_color, align=PP_ALIGN.CENTER) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 11 – ADVANCED MRI TECHNIQUES # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Advanced MRI Techniques in Brain Tumor Imaging", "DWI · DSC Perfusion · MRS · fMRI · DTI · Radiogenomics") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(5.5), Inches(5.75), fill_rgb=NAVY) add_text(slide, "KEY PARAMETERS", Inches(0.3), Inches(1.3), Inches(5.2), Inches(0.4), size=Pt(15), bold=True, color=YELLOW) adv = [ ("DWI / ADC:", True, YELLOW), ("▸ Low ADC = high cellularity = high grade", False, WHITE), ("▸ Restricted: PCNSL > Medullo > GBM > Low-grade", False, LTBLUE), ("▸ Abscess center: restricted | Tumor center: NOT", False, ORANGE), ("", False, None), ("DSC PERFUSION (rCBV):", True, YELLOW), ("▸ rCBV >1.75 = high grade (sensitivity 95%)", False, WHITE), ("▸ Oligodendroglioma: elevated despite low grade", False, ORANGE), ("▸ PCNSL: LOW despite avid enhancement", False, ORANGE), ("▸ Hemangioblastoma: highest of all", False, WHITE), ("▸ Use rCBV to target biopsy to highest grade area", False, WHITE), ("", False, None), ("MR SPECTROSCOPY (MRS):", True, YELLOW), ("▸ Cho↑ = membrane turnover = tumor activity", False, WHITE), ("▸ NAA↓ = neuronal loss", False, WHITE), ("▸ Cho/NAA >2 = malignant; >3 = highly malignant", False, ORANGE), ("▸ Lip/Lac = necrosis / anaerobic metabolism", False, WHITE), ("▸ 2-HG @ 2.25 ppm = IDH-mutant specific", False, ORANGE), ("▸ Taurine peak = medulloblastoma (relatively specific)", False, WHITE), ("▸ MRS abnormality extends BEYOND Gd enhancement", False, ORANGE), ("", False, None), ("TREATMENT RESPONSE:", True, YELLOW), ("▸ Pseudoprogression: within 12 wks of RT+TMZ", False, WHITE), ("▸ → MRS: Lip/Lac dominant, low Cho = treatment effect", False, LTBLUE), ("▸ Pseudoresponse: anti-VEGF → enhancement drops", False, WHITE), ("▸ → T2/FLAIR keeps growing despite less enhancement", False, LTBLUE), ("▸ True progression: Cho↑, rCBV↑, PET hypermetabolic", False, WHITE), ] add_multiline(slide, adv, Inches(0.3), Inches(1.75), Inches(5.2), Inches(5.2), size=Pt(10.5)) if imgs[7]: imgs[7].seek(0) add_image(slide, imgs[7], Inches(5.9), Inches(1.3), Inches(7.2), Inches(4.5)) add_rect(slide, Inches(5.9), Inches(5.85), Inches(7.2), Inches(0.45), fill_rgb=BLUE) add_text(slide, "Fig: Epithelioid GBM – (a) T2WI, (b) DWI restricted, (c) CE T1+Gd with dural tail, (d) ADC low, (e) PWI elevated rCBF in red, (f) MRS: Cho↑ NAA↓ (Cho/NAA markedly elevated)", Inches(5.95), Inches(5.87), Inches(7.0), Inches(0.42), size=Pt(10), color=WHITE, italic=True) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 12 – MASTER COMPARISON TABLE # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Master Imaging Comparison – Intra-Axial Tumors", "CT | T2 | Enhancement | DWI | rCBV | MRS Key Features") footer_bar(slide) col_hdrs = ["Tumor", "CT", "T2 Signal", "T1+Gd", "DWI", "rCBV", "MRS / Key Feature"] col_ws = [Inches(1.8), Inches(1.2), Inches(1.5), Inches(1.7), Inches(1.0), Inches(0.9), Inches(4.5)] col_xs = [Inches(0.2)] for w in col_ws[:-1]: col_xs.append(col_xs[-1] + w) table_data = [ ("GBM (IDH-wt)", "Hypodense ring", "Heterogeneous +halo", "Irreg ring", "+(rim)", "Very High", "Cho↑↑ NAA↓↓ Lip/Lac↑↑ | Cho/NAA>3"), ("Astrocytoma IDH-mut", "Hypodense", "Homogeneous bright", "None (Gr2)", "–", "Low", "Cho↑ NAA↓ 2-HG@2.25ppm | T2/FLAIR mismatch"), ("Oligodendroglioma", "Calcified", "Heterogeneous cortex", "Variable", "–", "Elevated!", "myo-inositol↑ Glu↑ | Ca++ on CT/SWI"), ("DIPG (H3 K27M)", "Expands pons", "Diffuse pons", "Variable", "+/–", "Variable", "Cho↑ NAA↓ | Wraps basilar artery"), ("Pilocytic Astro", "Cyst+nodule", "Cyst bright", "Nodule avid", "–", "Low", "myo-inositol↑ | Cyst wall NO enhancement"), ("Medulloblastoma", "Hyperdense!", "Iso/HYPOintense!", "Heterogeneous", "+++", "Moderate", "Taurine↑ NAA↓↓ | Lowest ADC"), ("Ependymoma", "Ca++ 50%", "Heterogeneous", "Moderate", "+/–", "Low-mod", "myo-inositol↑ | Squeezes through foramina"), ("PCNSL", "Hyperdense!", "Iso/HYPOintense!", "Homogeneous", "++", "Low-mod", "Cho↑↑ Lip↑↑ | Ghost sign with steroids"), ("Metastasis", "Variable", "Vasogenic edema", "Ring/solid", "–(ctr)", "Variable", "Normal Cho in halo | Disproportionate edema"), ("Ganglioglioma", "Calcified", "Heterogeneous", "Variable 50%", "–", "Low", "Mild Cho↑ | Chronic epilepsy in young pt"), ("Hemangioblastoma", "Cyst+nodule", "Cyst bright+flow void","Nodule avid", "–", "Very High!", "Mild Cho↑ | VHL association; high rCBV DDx"), ] row_h = Inches(0.45) for col_i, (hdr, x, w) in enumerate(zip(col_hdrs, col_xs, col_ws)): add_rect(slide, x, Inches(1.25), w, Inches(0.4), fill_rgb=NAVY) add_text(slide, hdr, x, Inches(1.26), w, Inches(0.38), size=Pt(10), bold=True, color=YELLOW, align=PP_ALIGN.CENTER) for row_i, row in enumerate(table_data): bg_c = LTBLUE if row_i % 2 == 0 else WHITE for col_i, (val, x, w) in enumerate(zip(row, col_xs, col_ws)): add_rect(slide, x, Inches(1.65 + row_i * row_h), w, row_h, fill_rgb=bg_c, line_rgb=BLUE, line_width=Pt(0.5)) txt_color = NAVY if col_i == 0 else (ORANGE if "!" in val or "↑↑" in val or "LOW" in val.upper() else GRAY) add_text(slide, val, x, Inches(1.66 + row_i * row_h), w, Inches(0.43), size=Pt(9), color=txt_color, align=PP_ALIGN.CENTER if col_i != 6 else PP_ALIGN.LEFT) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 13 – DIFFERENTIAL DIAGNOSIS: RING-ENHANCING LESION # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) bg(slide) header_bar(slide, "Differential Diagnosis: Ring-Enhancing Brain Lesion", "GRIING Mnemonic | Most Common Clinical Challenge in Neuroimaging") footer_bar(slide) add_rect(slide, Inches(0.2), Inches(1.25), Inches(6.3), Inches(5.75), fill_rgb=NAVY) add_text(slide, "G-R-I-I-N-G MNEMONIC", Inches(0.3), Inches(1.3), Inches(5.8), Inches(0.4), size=Pt(16), bold=True, color=YELLOW) ring_ddx = [ ("G – Glioblastoma", True, ORANGE), (" Irregular ring | T2 halo (contains tumor) | WM-based", False, WHITE), (" DWI: restricted rim | rCBV: very high", False, LTBLUE), ("", False, None), ("R – Radiation Necrosis", True, ORANGE), (" History of prior RT | 6+ months post-treatment", False, WHITE), (" MRS: Lip/Lac only, NO Cho | rCBV: low | PET: hypometabolic", False, LTBLUE), ("", False, None), ("I – Infection (Abscess)", True, ORANGE), (" THIN SMOOTH RING + DWI RESTRICTED CENTER (pus)", False, WHITE), (" Low ADC in cavity | Clinical: fever, elevated WBC", False, LTBLUE), ("", False, None), ("I – Infarct (subacute)", True, ORANGE), (" Follows vascular territory | Cortical + subcortical", False, WHITE), (" DWI restricted acutely | Gyral enhancement subacutely", False, LTBLUE), ("", False, None), ("N – Neoplasm (Metastasis)", True, ORANGE), (" GM-WM junction | Multiple lesions | Known primary", False, WHITE), (" Disproportionate edema | DWI center: unrestricted", False, LTBLUE), ("", False, None), ("G – Granuloma (TB / Toxo / Sarcoid)", True, ORANGE), (" Smooth ring | Contact/HIV history", False, WHITE), (" Toxo responds to empirical Rx; PCNSL does NOT", False, LTBLUE), ("", False, None), ("BONUS – D – Demyelination (Tumefactive MS)", True, ORANGE), (" OPEN RING / HORSESHOE enhancement", False, WHITE), (" Opening faces cortex | Young woman | WM lesions elsewhere", False, LTBLUE), ] add_multiline(slide, ring_ddx, Inches(0.3), Inches(1.75), Inches(5.9), Inches(5.1), size=Pt(11)) # Right panel summary box add_rect(slide, Inches(6.7), Inches(1.25), Inches(6.4), Inches(5.75), fill_rgb=WHITE, line_rgb=BLUE, line_width=Pt(1.5)) add_text(slide, "QUICK DECISION TOOL", Inches(6.85), Inches(1.35), Inches(6.0), Inches(0.4), size=Pt(14), bold=True, color=NAVY) quick = [ ("DWI RESTRICTED in center:", True, NAVY), ("→ Abscess (most specific)", False, GREEN), ("→ Also: PCNSL (whole lesion restricted)", False, ORANGE), ("", False, None), ("DWI RESTRICTED in rim only:", True, NAVY), ("→ GBM (solid hypercellular rim)", False, ORANGE), ("", False, None), ("rCBV HIGH:", True, NAVY), ("→ GBM, Metastasis, Oligodendroglioma", False, ORANGE), ("", False, None), ("rCBV LOW + restricted DWI + enhancement:", True, NAVY), ("→ PCNSL (classic triad)", False, ORANGE), ("", False, None), ("'Open ring' enhancement:", True, NAVY), ("→ Tumefactive MS (opening faces cortex)", False, GREEN), ("", False, None), ("MRS: ONLY Lip/Lac, no Cho:", True, NAVY), ("→ Radiation necrosis (NOT active tumor)", False, GREEN), ("", False, None), ("T2/FLAIR mismatch in solid non-enhancing glioma:", True, NAVY), ("→ IDH-mutant 1p19q-intact Astrocytoma", False, GREEN), ] add_multiline(slide, quick, Inches(6.85), Inches(1.85), Inches(6.0), Inches(5.0), size=Pt(11.5)) # ═══════════════════════════════════════════════════════════════════════════════ # SLIDE 14 – KEY TAKE-HOME MESSAGES # ═══════════════════════════════════════════════════════════════════════════════ slide = prs.slides.add_slide(blank) add_rect(slide, 0, 0, W, H, fill_rgb=NAVY) add_rect(slide, 0, Inches(0.9), W, Inches(0.08), fill_rgb=BLUE) add_rect(slide, 0, Inches(6.9), W, Inches(0.6), fill_rgb=BLUE) add_text(slide, "KEY TAKE-HOME MESSAGES", Inches(0.3), Inches(0.1), Inches(12), Inches(0.75), size=Pt(30), bold=True, color=WHITE, align=PP_ALIGN.CENTER) messages = [ ("1", "WHO 2021 changed everything – molecular markers (IDH, 1p/19q, MGMT, H3 K27M) are primary; histology is secondary."), ("2", "Enhancement ≠ Malignancy – 30-40% of GBMs may NOT enhance early; Grade 2 IDH-mutant gliomas rarely enhance."), ("3", "The T2/FLAIR halo of GBM ALWAYS contains infiltrating tumor cells – not just edema. Surgical margins must go beyond enhancement."), ("4", "T2/FLAIR mismatch sign: T2 bright + FLAIR iso/dark = IDH-mutant 1p19q-intact astrocytoma (Specificity >90%)."), ("5", "PCNSL disappears with steroids (Ghost Tumor). NEVER give steroids before biopsy unless herniation is imminent."), ("6", "DWI restriction ladder: PCNSL > Medulloblastoma > GBM solid rim > Abscess > Low-grade glioma."), ("7", "rCBV paradoxes: Oligodendroglioma = HIGH despite Grade 2 | PCNSL = LOW despite avid enhancement."), ("8", "Medulloblastoma: CT hyperdense + T2 hypointense + markedly restricted DWI = most reliable imaging triad."), ("9", "Gray-white matter junction + multiple lesions + vasogenic edema = Metastases until proven otherwise."), ("10", "Pseudoprogression (within 12 wks of RT+TMZ) vs. True Progression: use MRS (Lip/Lac vs Cho) + rCBV."), ] for i, (num, msg) in enumerate(messages): row = i % 5 col = i // 5 x = Inches(0.2) + col * Inches(6.55) y = Inches(1.1) + row * Inches(1.12) add_rect(slide, x, y, Inches(0.5), Inches(0.45), fill_rgb=BLUE) add_text(slide, num, x, y, Inches(0.5), Inches(0.45), size=Pt(18), bold=True, color=WHITE, align=PP_ALIGN.CENTER) add_rect(slide, x + Inches(0.55), y, Inches(5.9), Inches(0.45), fill_rgb=RGBColor(0x1E, 0x2A, 0x45)) add_text(slide, msg, x + Inches(0.6), y + Inches(0.02), Inches(5.8), Inches(0.5), size=Pt(11), color=WHITE) add_text(slide, "Source: Grainger & Allison's Diagnostic Radiology | WHO CNS5 2021 | Adams & Victor's Neurology 12E | Robbins & Kumar Pathology", Inches(0.3), Inches(6.95), Inches(12), Inches(0.35), size=Pt(10), color=LTBLUE, align=PP_ALIGN.CENTER) # ── SAVE ───────────────────────────────────────────────────────────────────── out = "/tmp/workspace/intraaxial-pptx/Intra_Axial_Brain_Tumors.pptx" buf = BytesIO() prs.save(buf) with open(out, "wb") as f: f.write(buf.getvalue()) print(f"Saved: {out}") PYEOF python /tmp/workspace/intraaxial-pptx/build_pptx.py

The base64 data needs strip-decoding. Let me fix the image loading:
Running Command

# Debug: check what the base64 string looks like python3 -c " import json, subprocess, base64 from io import BytesIO from PIL import Image raw = subprocess.check_output(['python', '/tmp/skills/shared/scripts/fetch_images.py', 'https://cdn.orris.care/cdss_images/021e540005efca79912c3154bc37e48ca8b100aaefcf5892dd6b5e20fd3901fa.png']) data = json.loads(raw) item = data[0] b64str = item['base64'] print('First 80 chars:', b64str[:80]) print('Has header?', b64str.startswith('data:')) # Try stripping the data: header if ',' in b64str: b64str = b64str.split(',', 1)[1] raw_bytes = base64.b64decode(b64str) buf = BytesIO(raw_bytes) img = Image.open(buf) print('Image OK:', img.format, img.size) "

Editing File

~/intraaxial-pptx/build_pptx.py

Successfully replaced 1 instance(s) of the string in '/tmp/workspace/intraaxial-pptx/build_pptx.py'
Running Command

python /tmp/workspace/intraaxial-pptx/build_pptx.py

Running Command

ls -lh /tmp/workspace/intraaxial-pptx/Intra_Axial_Brain_Tumors.pptx

Your PowerPoint is ready (2.4 MB, 16:9 widescreen):

Intra Axial Brain Tumors

Presentation · PPTX

What's inside (14 slides):

SlideContent
1Title Slide - Professional dark blue theme with seminar overview
2Definition & Classification - Intra-axial definition + WHO CNS5 categories
3GBM - Full CT/MRI/DWI/PWI/MRS + real GBM image (T2, T1+Gd, ADC)
4IDH-Mutant Astrocytoma - T2/FLAIR Mismatch Sign + real MRI image
5Oligodendroglioma - CT calcification + MRI + rCBV paradox + real image
6Diffuse Midline Glioma (DIPG) - H3 K27M + thalamic glioma real image
7Pilocytic Astrocytoma - Cyst+nodule pattern + real cerebellar image
8Medulloblastoma - CT hyperdense + DWI restriction + real CT/MRI/histology
9PCNSL - Ghost tumor + TME comparison image (GBM/Mets/PCNSL/Meningioma)
10Brain Metastases - Imaging features + GBM vs Metastasis comparison table
11Advanced MRI - DWI/PWI/MRS guide + multiparametric real imaging
12Master Comparison Table - All tumors vs CT/T2/Gd/DWI/rCBV/MRS
13Ring-Enhancing DDx - GRIING mnemonic + quick decision tool
1410 Key Take-Home Messages - Summary slide
This is a shared conversation. Sign in to Orris to start your own chat.